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Introduction 
 
Sub-Saharan Africa (SSA) is experiencing a rapid rise in in the prevalence of non-
communicable diseases (NCDs). Rapid demographic (growing and ageing population), 
socio-cultural (with lifestyle changes and eating habits) and economic transitions (with 
higher income and urbanization) are driving sharp rises in the risks and prevalence of 
diabetes, a risk factor for cardiovascular disease, with severe health and economic 
consequences.  
 
The impact of these transitions is evident. In 1990 the leading causes of death in SSA 
were HIV/AIDS, lower respiratory infections, diarrheal diseases, malaria and vaccine 
preventable diseases in children, but by 2012 stroke was in the top five, displacing 
vaccine preventable diseases.1  
 
In SSA, the fastest growing risk factor for morbidity and mortality is high body mass 
index, which has increased more than 200 percent between 1990 and 2010 and the 
second largest risk factor growth was in fasting plasma glucose, which jumped 80%. 
Between 1990 and 2010 the number of DALYs attributed to diabetes rose by 88%.2 Over 
90 percent of diabetes cases in SSA are Type 2, suggesting that modifiable risk factors 
are the major contributor to the burden of disease.3  
 
In SSA, tuberculosis ands antiretroviral medications required for the suppression of HIV 
also contribute to rising burden of type two diabetes.4 The confluence of these epidemics 
presents unique clinical and health systems challenges. In 2015 Africa was the only 
continent in the world where morbidity and mortality from infectious diseases still 
outnumbered those from NCDs.5 Yet, this balance will soon change as SSA, where health 
systems are not ready to manage this transition, experiences the full blown impact of 
rapid rise in diabetes and NCDs. 
 
The aim of the Lancet Diabetes and Endocrinology Commission on Diabetes in SSA is to 
provide a comprehensive analysis of the nature and magnitude of change in diabetes 
burden, preparedness of health systems to diabetes, and its health and economic 
consequences, to inform the development of an effective response.    
 
The Commission report is organized in nine sections. Introduction is followed by new 
estimates of current and future burden of diabetes by country. Section three explores 
characteristics of diabetes in SSA. Section four presents new analysis on health system 
readiness for managing diabetes. Section five is a new multi-country analysis of unmet 
need for diabetes. Section six presents projections of the economic consequences of 
diabetes. Estimates of costs and health benefits of scaling up interventions for treating 
diabetes follows. Section eight is a review of new service delivery models and 
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technologies for managing diabetes. Section nine identifies opportunities for an effective 
response to fight diabetes in SSA. 
 
Context and the burden of diabetes in sub-Saharan Africa 
 
The World Health Organization (WHO) estimates that in 2014 of the 422 million people 
with diabetes mellitus 25 million lived in the WHO Africa region, which corresponds to 
SSA. In 1980 globally there were 108 million people with diabetes, of which 4 million 
lived in SSA.6  
 
While the worldwide prevalence of diabetes increased by 80.9% from 4.7% in 1980 to 
8.5% in 2014, the prevalence in SSA had risen by 129.0%, from 3.1% in 1980 to 7.1% in 
2014. This rapid rise was only second to that observed in Eastern Mediterranean Region 
where the prevalence had risen by 132.2%, to reach 13.7% in 2014 from 5.9% in 1980, but 
higher than that observed in other regions of the world (Table 1) 
 
Table 1 
 
The International Diabetes Federation (IDF) estimates that in 2015 the prevalence of 
diabetes in SSA among adults aged 20-79 was 3.2% (uncertainty interval [UI] 2.1-7.6%), 
with 14.2 million people (UI 9.5-29.4 million) affected by diabetes. Seychelles had the 
highest estimated prevalence at 17.4%.  The IDF further estimates that by 2040, the 
prevalence of diabetes would rise to 4.2% (UI 2.6-7.3%) to reach 34 million people (UI 
23.7-67.7 million). The projected increase in the adult population (aged 20-79 years) 
from 441 million in 2015 to 926 million in 2040 will drive much of increase in the 
numbers of people with diabetes. Around 46,400 children aged 0-14 years, were 
estimated to have Type 1 diabetes.  The IDF estimated that in 2015, around 321,000 
deaths were attributed to diabetes, with 79% of these deaths occurring in persons aged 
60 years or less – a proportion higher than any other region in the world.7  
 
Other studies of prevalence of diabetes in SSA also confirm this rising trend, with rapidly 
increasing prevalence in rural populations.8 This rise is also true of older population 
groups. For example, a systematic review and of all published studies in the period 
2000-2015 on diabetes prevalence in north Africa and SSA in persons aged 55 years or 
more suggests an average prevalence of 13.8%, with a 95% confidence interval of 13.2-
14.3%.9 
 
The context: rapid transitions driving a rise in diabetes prevalence   
 
Three major drivers account for the rising diabetes prevalence: (i) change in prevalence 
itself (ii) change in population size and age structure and (iii) change due to interaction 
between change in prevalence and change in population size and age structure.10  
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The first driver, change in prevalence itself, is influenced by economic, socio-cultural and 
nutritional transitions, which are leading to urbanisation, changing food availability, new 
eating habits, and evolving lifestyle and work practices to produce higher levels of 
obesity – the greatest contributor to the diabetes epidemic – which is influenced by 
genetic factors, and rising fasting plasma glucose levels. Rapid economic transition is 
evident: the International Monetary Fund expects sustained strong growth in economies 
of these countries with a projected increase in the Gross Domestic Product (GDP) per 
capita of 2.5% each year through to 2020.11 
 
Economic transition is driving urbanisation in SSA, with urban population projected to 
rise from 360 million in 2015 (37.4% of total) to 732 million (46.6% of total).12 Although 
few studies have compared the prevalence of diabetes in rural and urban populations in 
the same country, published studies estimate prevalence of 0.1% in in rural areas of 
Ghana13, 2.8% in rural Angola14, 3.9% in South Africa15, 6.1% in rural areas and 13.4% in 
urban areas of Guinea16, and 5.3 % in urban slum Nairobi17, 10.1 for men and 11.2% for 
women urban dwellers in Cameroon18, and 17.9% in Dakar Senegal19. 
 
Urbanisation has affected the global nutritional transition and obesity levels which have 
reached 5.3% in Uganda to 30% in Nigeria and 45.7% in South Africa.20 The availability 
of cheap energy sources, such as vegetable oil, has greatly increased calorie intake and 
resulted in profound changes in body composition in populations globally as well as SSA.  
 
The dynamics of the obesity epidemic are well illustrated by the demographic and health 
surveys undertaken in seven African countries at intervals of 10-13 years over the period 
1992-2005. The surveys indicate that in city-dwellers 31.4% of women were overweight 
or obese, (38% in Kenya to 28-29% in Burkina Faso and Senegal), with an increase of 
one third in the prevalence of urban overweight/obese in just over a decade. Obesity was 
correlated with household income, education, and working status of women; the most 
rapid increase (50% overall) was in the poorest urban dwellers, especially women, but in 
women with secondary education or higher obesity levels declined by 10%.21  
 
While access to food is still a major daily challenge in most countries of SSA, a larger 
body size is perceived as a sign of affluence and good living. In many communities it is a 
deeply rooted status symbol conferring respect, influence, health and 
attractiveness.22,23,24 Being overweight also has positive connotations in societies in 
which a strong stigma is attached to weight loss and wasting associated with 
HIV/AIDS25; which paradoxically may mean that obesity may be perceived as an 
indication of health.  
 
The second driver, population growth: the population of SSA is projected to rise from 
962 million in 2015 to 1.24 billion in 2025 and 1.57 billion in 2035.26 
 
The third driver, population structure, is also projected to change rapidly, producing an 
ageing population – with the number of persons aged 50 years or more projected to 
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increase from 95 million in 2015 to 186 million in 2035.27 Average life expectancy is 
projected to rise from 57.2 years in 2010-2015 to 65.9 years in 2035-2040.28  
 
 
Prevalence of obesity and diabetes in sub-Saharan Africa: empirical 
analysis of national surveys 
 
While many studies have estimated the prevalence of diabetes and obesity in SSA, few 
empirical analyses at country level exist. We estimated the prevalence of diabetes in 10 
countries using individual level patient data from 10 nationally representative surveys to 
obtain an up do date estimate. The surveys included the WHO Stepwise Approach to 
Surveillance Surveys (STEPS) undertaken in 2005-2013 in Benin (2008), Comoros 
(2011), Guinea (2007-08), Liberia (2011), Mozambique (2005), Tanzania (2012), Togo 
(2010) and Seychelles 2013), a Demographic and Health Survey undertaken in Namibia 
in 2013, and the South African National Health and Nutrition Examination Survey 
undertaken in 2012.  
 
The data sources and methodology are discussed in detail elsewhere and a summary 
included in supplementary appendix.29 We approached WHO to obtain data from the 
STEPS surveys, which have been made available to other researchers, but were refused 
access.30 We therefore, approached separately each country where STEPS surveys were 
undertaken and obtained responses and data from 12 of them. We excluded two surveys 
from DR Congo due to data incompleteness. The complete pooled dataset included 
39,062 individuals across 10 countries over the period from 2004-2014. 
 
The analysis reveals a strong relationship between increasing age and the prevalence of 
diabetes and obesity, with higher prevalence for women across all age groups. Cross-
country prevalence of diabetes ranged from 1.3% in Benin to 21.6% in Seychelles based 
on biomarker measurement and self-reported use of diabetic medications. Age stratified 
prevalence level of diabetes revealed rising prevalence levels with age, with levels 
reaching 35-30% in men and women in South Africa and Seychelles (Figure 1).  
 
Figure 1 
 
Obesity levels (body mass index >25) also varied across countries, with age-stratified 
levels ranging from less than 10% in men aged 25-39 years old in Benin and Togo to 
more than 70% in South Africa and almost 80% in women aged 55-65 years (Figure 2). 
 
Figure 2 
 
The prevalence of diabetes and obesity also varied in populations in employment and in 
those not employed, with higher levels observed in the employed populations across all 
countries (Appendix). 
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Rising diabetes and double burden of disease in SSA countries, has major implications 
for health systems, which are not ready to manage this rapid transition.31 We explore in 
the next section the characteristics of diabetes in SSA, which needs to be well understood 
if an effective response is to be developed. 
 
Characteristics of Diabetes in Africa 
 
Diabetes was a rare disease until about a century ago, but now affects up to a third of the 
population in some parts of the world32, indicating that its causes are predominantly 
environmental. The relative risk of developing diabetes within a population is however 
modulated by genetic susceptibility as well as environmental exposures.  
 
Diabetes in Africa is different 
 
Sub- Saharan Africa, the cradle of mankind, is a region with greater genetic variation 
than the rest of the world put together, together with an exceptionally wide range of 
environmental variation. The genetic and phenotypic features of diabetes vary from one 
population and culture to another, due to environmental differences and variations in 
genes which affect body composition and metabolic function. Because of this variation, 
Western models of diabetes care are not necessarily appropriate for unmodified use in 
other parts of the world.   
 
Although there is probably no place on earth where the environmental and genetic 
determinants of diabetes exhibit greater variation than in SSA, the African population 
has been studied in less detail than many other populations around the world. African 
studies of excellent quality do exist, but their generalizability to other parts of the 
continent is not well established. This environmental and genetic diversity is matched 
with political diversity and many differences in health systems in SSA.  
 
The spectrum of diabetes in Africa  
 
Diabetes is classified into primary varieties, for which no extrinsic cause has been 
identified, and secondary varieties for which there is a known extrinsic cause.  
Primary diabetes is classed as type 1 and type 2. Both forms have risen in prevalence over 
the past half-century. The hallmark of type 1 diabetes is severe insulin deficiency which, 
if untreated leads to the hyperglycaemic emergency of diabetic ketoacidosis (DKA). It is 
due to immune-mediated loss of pancreatic beta cells and can occur at any age, although 
it typically affects younger non-obese people and has its greatest impact in childhood 
and adolescence. Its incidence began to rise in Western populations around the middle 
of the last century, and it is still increasing in many parts of the world. Early onset is 
associated with higher degrees of genetic susceptibility, and there is a secular trend 
towards earlier onset suggesting increased penetrance of the disease; a similar shift has 
been reported in Africa.  
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The cause of type 1 diabetes is unknown, but susceptibility is strongly associated with 
certain HLA types, whereas other types are strongly protective. The rapid secular 
increase in the condition points to environmental causation superimposed upon genetic 
susceptibility. Estimates of its prevalence have risen sharply in some parts of Africa, 
most probably as a consequence of improvements in case detection (Appendix: Rwanda 
case study), but mortality levels are very high due to failures in diagnosis and 
management including lack of access to insulin.33     
 
African-Americans were once considered “immune to diabetes” 34 and the condition was 
considered very uncommon in Africa itself until the 1960s, when studies first showed an 
increasing prevalence of obesity, hypertension and diabetes in city-dwellers in Southern 
Africa35. The prevalence of type 2 diabetes subsequently rose rapidly in Africa, in parallel 
with the rise of obesity, and early-onset forms of type 2 diabetes associated with severe 
obesity have emerged in many susceptible populations including those of African 
descent. These may sometimes overlap with type 1 diabetes, a condition that has been 
called “double diabetes”.  
 
Type 2 diabetes is best viewed as a syndrome exhibiting genetic, metabolic, and clinical 
heterogeneity, and its impact upon metabolic pathways ranges from decreased insulin 
secretion to increased glucose production and insulin insensitivity. The relative 
contribution of such imbalances may differ between populations.36  
 
While international guidelines are heavily influenced by western practice, the African 
population has been studied in less detail, and shows important differences from other 
parts of the world. For example, in Africa, most people affected by type 2 diabetes are 
30-59 years old, whereas most people in Europe with diabetes are aged over 60 years.37 
Type 2 diabetes is strongly associated with obesity in all parts of the world, but Africans 
may be twice as likely to develop diabetes for a given level of body mass, as compared 
with people of European origin. These observations suggest that although the 
“epidemiological transition”, driven by high rates of urbanization and associated 
behavioural risk factors influencing diet and physical activity has had a world-wide 
impact, the African population may be inherently susceptible to the diabetogenic effects 
of “westernization”.  
 
The biological mechanisms underlying heightened susceptibility to diabetes are 
unknown, and may include evolutionary adaptation to ancestral famine (the “thrifty 
genotype” hypothesis). In addition, there is increasing recognition that developmental 
influences can affect long-term risk of disease. Fetal exposure to maternal malnutrition 
generates a phenotype that promotes survival in a nutrient poor environment but 
substantially increases the risk of diabetes and cardiovascular disease in the presence of 
abundant nutrition.38 Rapid weight gain following a period of childhood stunting is a 
well-recognised risk factor, as is gestational diabetes with its risk of intergenerational 
transfer of diabetes to the offspring.  
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The speed of epidemiological transition in Africa has been such that high rates of 
infectious disease, notably tuberculosis and HIV, coexist with a rising prevalence of 
NCDs such as diabetes. Tuberculosis and diabetes interact, each predisposing to the 
other39, and HIV – itself associated with an increased risk of vascular disease – is treated 
with anti-retroviral (ARV) drugs which may provoke or exacerbate diabetes40.  
 
Type 2 diabetes is often preventable – or even reversible – by low cost measures such as 
lifestyle intervention41. Its high mortality is largely due to accelerated cardiovascular 
disease, and the condition typically – but by no means always – occurs in association 
with obesity, hypertension, lipid abnormalities and other vascular disease factors. It is 
also associated with obesity-related forms of cancer.  
 
Most complications of type 2 diabetes can be prevented with existing forms of therapy 
when properly applied. Although many people with type 2 diabetes can be brought into 
safe glucose control with lifestyle change and oral medication in the early stages of their 
disease, their ability to secrete insulin diminishes with time, and insulin replacement 
therapy often becomes necessary. Ongoing monitoring and escalation of glucose-
lowering therapy is thus an essential element of diabetes management.  
 
Clinical types of diabetes in Africa 
Variant forms of diabetes have been described in people of African descent since the 
1950s, and have been associated with metabolic decompensation resulting in ketosis.  
 
Reports from African-American populations indicate that the condition is seen in new-
onset patients, typically middle-aged, overweight, and with a family history of type 2 
diabetes in 80% of cases. Despite presentation with ketosis, such individuals can usually 
be managed without insulin over the longer term.42 The extent to which it represents a 
true variant form of diabetes remains uncertain, but it does show the need for more 
detailed investigation of the pathophysiology of diabetes in people of African descent.  
 
Secondary diabetes falls into three main categories. The first category is associated with 
a defined, typically monogenic, genetic syndrome. The second occurs when insulin 
secretion is compromised by pancreatic damage, such as acute or chronic pancreatitis or 
pancreatic cancer. The third arises when the onset of diabetes is associated with extra-
pancreatic factors affecting insulin resistance, for example hyper-secretion of hormones 
that antagonize the secretion of insulin, or some types of drug-induced diabetes43. 
Secondary diabetes is relatively uncommon, affecting fewer than 5% of patients, but it is 
important to diagnose it correctly, since this can has a major impact upon its treatment 
and prognosis. 
 
Malnutrition related diabetes has been reported from tropical areas in Africa, South 
America and South Asia, but its classification as a distinct subtype has been 
controversial.44 Also known as fibrocalculous pancreatic diabetes, it is usually seen in 
underweight, malnourished patients and is characterized by severe hyperglycaemia 
without ketosis, high insulin requirements, and lack of autoimmunity, making it distinct 
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from classical type 1 diabetes.  Patients, predominantly male, have a later age of onset, 
very low BMI, low socioeconomic status and a history of malnutrition. The contribution 
of exocrine pancreatic disease to diabetes in western populations has probably been 
underestimated, and its contribution to diabetes in Africa is still largely unknown. 
 
 
The sub-Saharan African environment for diabetes 
 
The rapid rise in diabetes prevalence is driven by many factors including increasing 
obesity – influenced by economic, socio-cultural and nutritional transitions – and 
increasing age45. The prevalence of obesity is highly dependent upon the environment, 
and the proportion of overweight people in a population reflects living conditions, 
cultural beliefs and food availability. Within that population, individual risk of obesity 
will depend upon a combination of genetic, cultural and socioeconomic determinants. 
This is reflected in the wide variation in the prevalence of obesity in sub-Saharan 
Africa.46   
 
Urbanization has played a key role in the global nutritional transition, and the 
availability of cheap energy sources has greatly increased calorie intake and resulted in 
profound changes in body composition in populations around the world47. The health 
burden of these changes varies between ethnic groups, due to differences in patterns of 
fat deposition and their cardiac and metabolic consequences, which become manifest in 
African and Asian populations at lower levels of BMI than in those of European 
descent.48,49  
 
Further to these disparities between countries, there are also major gradients between 
the prevalence of obesity in urban and rural populations; differences between countries 
may thus reflect the proportion of city-dwellers within a country or variations in 
sampling technique. The dynamics of the obesity epidemic were well illustrated by 
demographic and health surveys undertaken in 7 African countries at intervals of 10-13 
years over the period 1992-2005. At the time of the latest survey in city-dwellers, 31.4% 
of women were overweight or obese, with a range from 38% in Kenya to 28-29% in 
Burkina and Senegal. The prevalence of urban overweight/obesity had increased by one 
third in a little over a decade, with a year-on-year increase of 5%. Obesity was inversely 
associated with household income and education, and the most rapid increase (50% 
overall) was seen in the poorest urban dwellers, notably women. In contrast, a fall of 10% 
was seen in women with secondary education or higher.50 
 
These trends are consistent with increased food availability, especially refined energy-
dense foods which have been adopted at the expense of more varied traditional diets 
which provide more essential nutrients.  
 
The genetic contribution to diabetes in sub-Saharan Africa 
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Although genes predisposing to diabetes influence the relative risk of diabetes within a 
given population, environmental factors determine the absolute risk of diabetes within 
the population as a whole. Age and obesity are the two major environmental influences 
upon type 2 diabetes, and major obesity increases the risk of future diabetes by 80-100 
fold, an order of magnitude greater than the best available genetic markers of risk. It is 
nevertheless important to define the genetic contribution to the diabetes epidemic in 
Africa, in order to define future susceptibility and (potentially) to permit future 
development of more targeted therapies.  
 
Mankind originated in Africa, and the exodus of daughter populations from Africa 
passed through genetic bottlenecks created by small founder populations with rapid 
subsequent expansion. African populations are in consequence characterized by greater 
genetic diversity in both the nuclear and mitochondrial genomes together with lower 
levels of linkage disequilibrium (an indication of more ancient ancestry) than non-
African populations. At least 13 genetically distinct ancestral African populations have 
been described, and African people are also characterized by genetic adaptations, which 
have evolved in response to infectious and nutritional challenges in the past 
environment.51,52 This complex and diverse genetic structure has been relatively 
understudied, and it seems likely that considerable genetic variation and disease-
associated genes remain to be uncovered within the African population. 
 
Some gaps have been filled by the study of African-American populations, and 
comparison between groups of differing ethnicity in “melting pot” societies such as the 
USA. This is a potentially useful way of disentangling environmental from ethnic 
differences in the presentation of diabetes, but such comparisons must be interpreted 
with caution. African-Americans mostly originated from West or Central Africa and are 
therefore not representative of SSA as a whole, or indeed of their own parent 
populations.53 Admixture with other ethnic groups and socio-economic differences are 
also potential confounders of such comparisons between migrant populations.   
 
Since much of our evidence about the genetic characteristics of diabetes in Africans 
comes from the study of African-Americans, African-based studies are badly needed. It is 
nonetheless clear that African-American populations have a two-fold risk of type 2 
diabetes compared with those of European extraction54, and also have a much higher 
current prevalence of type 2 diabetes than most African populations. This may indicate 
future patterns of diabetes development in Africa itself.  
 
Genetics of type 1 diabetes in Africa 
Although GWAS studies have identified more than 40 genetic loci in association with 
type 1 diabetes in all populations, by far the greatest contribution comes from the HLA 
region, with odds ratios ranging from 0.02 to >11 for specific DR-DQ haplotypes; only 2 
other loci achieve an odds ratio in excess of 1.5.55 Notably, genes associated with type 1 
diabetes influence immune mechanisms rather than beta cell function.  
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The dominant role of the HLA system in conferring susceptibility to diabetes is seen in 
all populations worldwide, but the relative importance of specific alleles varies with the 
genetic architecture of the population concerned. Large-scale analyses have yet to be 
performed in SSA, but studies in African Americans show some unique associations. In 
particular the DR4/DR9 genotype, which contains an African-derived “DR9” haplotype, 
confers an odds ratio of 30.88, comparable to the highest risk genotypes found in 
European origin populations.56  
Genetics of type 2 diabetes in Africa 
To date, nearly 80 genetic loci have been implicated in susceptibility to type 2 diabetes in 
global populations57, but none have an effect comparable to that of the HLA region in 
type 1 diabetes. Populations vary in terms of the relative contributions of insulin 
resistance and beta cell deficiency to the onset of diabetes, but most of the genes known 
to be associated with type 2 diabetes influence beta cell function rather than insulin 
resistance.58 Furthermore, progression of established diabetes is predominantly related 
to declining insulin secretion rather than increasing insensitivity to its action.59  
 
As with type 1 diabetes, the same genes tend to emerge in diverse populations. GWAS 
analysis of type 2 diabetes in African Americans identified three known loci at genome-
wide significance (TCF7L2, HMGA2 and KCNQ1) together with two novel loci (HLA-B 
and INS-IGF2), indicating the existence of Africa-specific susceptibility genes.58 Africa 
itself has been incompletely studied, but a genome-wide association study is being 
conducted on type 2 diabetes among continental African populations in the H-3 Africa 
project [http://h3africa.org ]. Epigenetic changes are know to have differential effects on 
diabetes incidence dependent on population studied60, however, little is known about the 
effects of the epigenome on African populations. 
 
Sub-Saharan Africans appear to have undergone natural selection for a range of genomic 
regions associated with obesity and type 2 diabetes. This may explain why a study that 
mapped the genetic risk of type 2 diabetes by measuring the allelic frequency of 16 
associated variants in 51 populations suggested that Africans face the highest known 
genetic risk for type 2 diabetes (http://geneworld.stanford.edu/hgdp.html). This 
selection has implications for the future prevalence of type 2 diabetes in SSA.  
 
Type 2 diabetes is a syndrome, and analysis of the genetic contribution to 
hyperglycaemia does not capture the full prognostic implication of a diagnosis of 
diabetes. For example, in the Third National Health and Nutrition Examination Study 
(NHANES III), individuals over the age of 50 who had diabetes but no features of the 
‘metabolic syndrome’ did not have an increased risk of coronary heart disease, as 
compared with non-diabetic individuals (7.5% diabetes: 8.7% non-diabetes), whereas 
individuals with both diabetes and metabolic syndrome features had a 19.2% age-
adjusted prevalence.61 Equally, it has long been known that vascular disease, 
hypertension and diabetes aggregate in African-American pedigrees.62  Given the high 
prevalence of adverse risk constellation in African Americans, further study of its genetic 
basis in continental Africa is needed.63  
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The challenge of diabetes in in sub-Saharan Africa 
 
Type 1 Diabetes 
The recorded incidence of type 1 diabetes in SSA appears relatively low compared with 
many other parts of the world, with six of the seven published studies showing incidence 
of <3 cases per 100,000 <15 years per year, and Sudan at 10.1 cases.64 These figures are 
almost certainly an underestimate as awareness of the presenting features of childhood 
onset diabetes is low in the general population and among medical personnel.  
 
Little is known about the genetic and phenotypic characteristics of juvenile diabetes in 
SSA. Autoantibodies are less common than in studies in Western populations but it is 
not clear whether this is due to differing methodologies or aetiologies.  There is some 
variation in HLA alleles affecting predisposition to type 1 diabetes.65 
 
The peak age of onset of type 1 is around 12 years in western countries, but appears to 
have been deferred into the late teenage years in SSA.66 This is possibly due to a 
combination of two factors, since younger children are less likely to be diagnosed and 
treated, and environmental factors that may have accelerated onset of the condition in 
western countries may still be lacking in SSA. 
 
Countries in north-east SSA (Somalia, Eritrea, northern Ethiopia, Djibouti) appear to 
have considerably higher incidence rates compared with African countries south of this 
region, as well as populations in the Middle-East and north Africa.67 
 
The apparent prevalence is also low, probably as a result of high attrition of diagnosed 
cases. Medical care is especially compromised by limited health professional experience; 
lack of access to insulin, blood glucose monitoring equipment, diabetes education; 
distance to treatment centres; and political instability68 (Figure 3). Various studies  have 
demonstrated the very high relative cost for families of diabetes care for a child or young 
person with diabetes – for instance in Benin, Burkina Faso, Central African Republic, 
Ivory Coast, Malawi and Mauritania the annual cost of consumables for minimal 
reasonable care for a child with type 1 ranged from 74-377% (median 126%) of per capita 
Gross National Income.69  
Figure 3 
 
The cost includes not only supplies (insulin, syringes and blood glucose meters and 
strips) but also laboratory tests such as HbA1c, and sometimes hospitalisation costs. 
There are also indirect costs such as travel costs (travel distances of over 200km are 
common), missed parental work time and others. Costs are particularly high when the 
cost of blood glucose strips per day is factored in – with the median cost of a blood 
glucose strip in seven African nations being $0.50 (range $0.20-$1.20). Even at two tests 
per day, this supply is usually more expensive than a supply of insulin. The financial and 
emotional impact on young people and their families is often severe, and undoubtedly 
many die due to lack of access to and affordability of care.71  
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Even safe insulin storage is a problem – many families do not have access to 
refrigeration and so clay pots are used for evaporative cooling. Encouragingly, 
preliminary evidence indicates that these methods are effective in reducing storage 
temperatures down towards room temperature (Ogle – personal correspondence).  
 
Earlier reports from SSA document an appallingly high mortality for type 1 diabetes. 
Beran and colleagues have estimated life expectancy for children aged less than 15 years 
in Mozambique and Zambia on the assumption of equal incidence in rural and urban 
areas.70  In Mozambique, the estimated life expectancy was 3.5 years, and a child 
developing diabetes in a rural area was unlikely to survive for more than a year.72 Data 
from some other countries is a little more encouraging: in Soweto in South Africa from 
1982-92, the mortality rate was 16% over 10 years (with half the deaths from renal 
failure, with others from ketoacidosis, hypoglycaemia and sepsis); a follow-up study 
showed 43% mortality at 20 years’ duration.71 Recent data from Rwanda showed a five-
year survival of 93.8%, but the status of a number of patients was unknown and 
mortality could have been up to almost triple the crude mortality rate of 13.9 per 1,000 
patient years. The same study found high rates of microalbuminuria, retinopathy, 
neuropathy and hypertension.67 These figures should be set against in more affluent 
parts of the world, where life expectancy for young people diagnosed with type 1 is now 
only a few years less than that of the general population.72  
 
Experience has shown that that the number of cases with type 1 diabetes rises sharply as 
interventions become available, diagnosis improves and mortality from acute 
complications (diabetic ketoacidosis and severe hypoglycaemia) falls. In Tanzania, 
known numbers of young people with type 1 rose from 50 in 2005 to 1,200 in 2015.73 In 
Mali, known numbers of young people with insulin-requiring diabetes <25 years of age 
have risen from 14 in 2007 to over 350 in 2016, and in Rwanda from 35 to over 900 (See 
Appendix Rwanda Country Profile). According to international convention, estimates 
have to date focused on children under the age of 15 years. The only published 
prevalence figure that covers the young adult age group is from Rwanda – 16.4/100,000 
population <26 years.67 As noted, type 1 diabetes presents later in SSA, and children with 
diabetes also grow up (if they survive). The actual number of people with type 1 in Africa 
will thus be an unknown multiple of those under 15 years – in Rwanda there are 3.5 
times as many cases aged <26 years as <15 years. 67 
 
In the absence of adequate care for people with type 1 diabetes within health systems, in 
the last 12-years, multiple initiatives have developed to improve care of children and 
adolescents with diabetes in Africa. The International Diabetes Federation Life for a 
Child Program (LFAC) commenced support in Africa in 2004 and now assists 9,873 
young people aged <26 years in 20 countries. The Changing Diabetes in Children 
Program (CDiC ) commenced in Africa in 2009 and assists over 7,700 young people in 
seven countries. Both programs work by strengthening the main existing diabetes 
centres in each country, providing insulin, blood glucose meters and strips, HbA1c 
testing, educational materials and health professional training, capacity building, and 
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other support including technical support in developing registers. Documentation of 
impact is now appearing67, with sharply falling HbA1c levels in some countries.  
  
‘Ageing-out’ of programmes – i.e. cessation of support at a given age – is an increasing 
problem. LFAC, for example, provides support until 26 years of age. After this age, there 
are some initiatives for example, tied to vocational training in Rwanda, microfinance in 
Tanzania, and support from Insulin for Life and Marjorie’s Fund in some countries, but 
there is a large gap still at this age group. 
 
Type 1 is a complex disorder, and diabetes education of the young person, their family, 
and health professionals, tailored to culture, language and education/knowledge levels, 
are critical in achieving good outcomes.  LFAC, CDiC, and institutions in DR Congo, 
Sudan, South Africa have developed resources for diabetes education for children, their 
families and health professionals [http://www.idf.org/lifeforachild/diabetes-education-
resources]. LFAC and the International Society for Pediatric and Adolescent Diabetes 
have also published Pocketbook Guidelines for use in under-resourced countries.  
 
There are also nascent efforts to train specialists in countries in SSA. For example, in 
2008, Gertrude Children’s Hospital and other institutions in Nairobi, in partnership with 
the European Society of Pediatric Endocrinology, established the Pediatric 
Endocrinology Training College in Africa..  A second college opened in Lagos, Nairobi in 
2013. The course runs for 18-months, with two six-month placements in the College and 
two three-month periods at the fellow’s home institution. As at 2015, 54 paediatric 
endocrinologists from 12 African countries have been trained in Nairobi alone.74  
 
Type 2 diabetes in sub-Saharan Africa  
 
Few large scale studies have been performed on the prevalence of type 2 diabetes in 
Africa75 and most countries do not routinely collect population level data on diabetes 
burden. A systematic review of reports of diabetes in people age >55 years in Africa 
reported an overall prevalence of 13.7%, higher in urban than in rural environments 
(19.7% vs. 7.9%). The prevalence was higher as measured by oral glucose tolerance test 
than by measurement of fasting glucose (23.9% vs. 10.9%), and in non-STEPS than in 
STEPS studies. (17.1% vs. 9.6%).9  The study highlights the challenges in reaching an 
accurate estimate of the prevalence of diabetes, which is often asymptomatic or 
unrecognised in older people. Unfortunately, the two main diagnostic measures, fasting 
plasma glucose and the oral glucose tolerance test identify different groups of people, 
and the 2-hour value on the oral glucose tolerance test identifies a higher proportion of 
people in ageing populations compared with fasting plasma glucose measurement.76  
 
From a clinical perspective, presentation with diabetes is often delayed in SSA and the 
great majority of people with overt diabetes will have unequivocal increases in random 
glucose and will therefore be diagnosed correctly whatever the test employed.76 Choice of 
a cut-off point for borderline cases or choice of test (fasting plasma glucose, oral glucose 
tolerance test or HbA1c) are thus of less immediate relevance in the context of routine 
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clinical diagnosis and care, but this issue is nonetheless of great practical importance for 
the future as earlier detection of the condition becomes feasible.76 Screening for diabetes 
is not recommended, even in affluent environments,77 but opportunistic testing of at-risk 
patient groups (for example, those with TB) will become more widespread as health 
services improve, and guidance is needed on the most cost-effective means of doing so. 
The immediate priority, however, is to identify and treat those at greatest need. 
 Gestational diabetes in sub-Saharan Africa 
 
In 2013, the global prevalence of hyperglycaemia in pregnancy in women 20-49 years is 
estimated to be 16.9%, affecting 21.4 million live births. More than 90% of these cases 
are estimated to occur in low and middle-income countries. Worldwide there is 
significant variability in prevalence due to difference in the diagnostic criteria used, but 
Africa ranks second after south east Asia.78 
 
As the epidemic of type 2 diabetes spreads to younger people, the prevalence of GDM is 
likely to rise sharply in Africa. Systematic reviews of studies conducted in some African 
countries, notably Nigeria, found a prevalence ranging from 0 to 13.9%. Higher 
prevalence was noted in studies done after the year 2000 and those which used more 
current diagnostic criteria. A study of around 1000 pregnant women in Nigeria, for 
example, found prevalences of 3.8%, 8.1%, 7.5% and 8.6% respectively when modified 
IADPSG and original IADPSG criteria were used.79  
 
Gestational diabetes has well-recognised associations with adverse maternal and 
perinatal outcomes and long-term sequelae including pregnancy-induced hypertension, 
preeclampsia, ante-partum haemorrhage, caesarean section, preterm birth, birth 
trauma, congenital anomalies and perinatal mortality.80 Women with GDM are at high 
risk for developing type 2 diabetes, with up to seven-fold increased risk. Furthermore, 
their offspring have higher susceptibility to glucose intolerance and obesity later in life.  
 
There have been several studies of diabetes in pregnancy in Africa, although mostly from 
urban areas and with relatively few participants in the majority.  A study from Kenya in 
1982 revealed a perinatal mortality rate of 254 in 1000; five times higher than in the 
non-diabetic population  (based on 14 perinatal deaths in 55 pregnant women with 
diabetes, over a 6-year study period).81  In Sudan, the influence of obstetric factors and 
indices of maternal metabolic control on perinatal morbidity and mortality were studied 
in 88 pregnant diabetic and 50 pregnant non-diabetic control women. The incidence of 
neonatal complications was 54.4% of in diabetic mothers vs. 20% in other mothers 
(p<0.001), and maternal hyperglycaemia was identified as the contributing factor.82.  
 
The benefits of treating diabetes in pregnancy have been widely shown – in South Africa, 
a reduced  overall perinatal mortality was seen in treated compared to untreated women 
with diabetes in pregnancy.83  An earlier study found a perinatal mortality of 10 in 1000 
in the treated group with diabetes in pregnancy compared with the rate of 145 in 1000 in 
untreated group.84  However, the form of treatment to use is debated. In South Africa, 
the form of therapy during pregnancy for 379 women with type 2 diabetes impacted on 
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perinatal mortality; with a higher rate (125 per 1000 births) in women managed on 
metformin and glibenclamide  alone compared to  women converted to insulin from oral 
agents (28/1000) and in the group treated with insulin alone/converted from diet to 
insulin (33/1000). However, there was no relationship between early exposure to 
metformin and glibenclamide and risk of foetal anomalies.85 Perinatal mortality rate was 
similar, at 28/1000 live births in a study of 214 mothers with type 2 diabetes, who 
delivered at Baragwaneth Hospital in Soweto South Africa, all but five of whom were 
managed with insulin.84 All of these studies were observational, however, and 
randomised controlled trials comparing agents in Africa need to be done. 
 
Although the prevalence of GDM is rising, risk factors and optimal treatments unique to 
SSA are not clear. Reported risk factors for GDM, in SSA as elsewhere, are overweight 
and/or obesity, family history of type 2 diabetes, GDM in a previous pregnancy, previous 
still birth, previous macrosomic child and age >30 years. At present time, selective GDM 
screening programmes offer the most cost-effective option in SSA, but will require the 
development of simple criteria for identifying women at risk, which may differ in 
countries across SSA.86,87,88 As yet no studies have assessed whether the ADA or IADSPG 
criteria are most applicable to women in SSA. 
 
Given that SSA is undergoing rapid demographic and epidemiological transition with the 
associated changes in diet and lifestyle, and the burden of diabetes in pregnancy is 
already increasing rapidly, and there is a high risk that many women with diabetes in 
pregnancy will either go undiagnosed or will be inappropriately managed. 
 
Better understanding of the prevalence and the risk for GDM in SSA will help guide 
studies of management approaches and also more targeted interventions. In resource-
rich countries, insulin still remains the benchmark for managing hyperglycaemia in 
pregnancy, but oral agents are less expensive and are usually better tolerated and 
accepted. The two oral agents commonly used are metformin and glibenclamide. Of 
these, metformin is more effective, more readily available and more commonly used in 
SSA. However, trials are sorely needed to ensure that these agents are as effective and 
safe as insulin in pregnant women in SSA. High quality patient-centred care is also 
required to enable informed and shared decision making with patients. 
  
Diabetic nephropathy in sub-Saharan Africa 
 
Globally, prevalence of chronic kidney disease (CKD) has risen. In 2010, globally 
hypertension was the leading cause of deaths from kidney disease.89 In 2013 the number 
of cases attributable to hypertension fell, but that attributable to diabetes rose.90 
 
Although data from SSA are lacking estimates suggest that CKD prevalence in adults is 
around 13.9% (95% CI 12.2–15.7)91, and between 4-24% in those with diabetes92. A meta-
analysis of 64 307 people with CKD in SSA showed a mean age of 41·4 years (SD 9·9). Of 
these 46 494 (72%) had diabetes, 2765 (4%) were obese, 37 169 (58%) were HIV positive, 
and 7845 (12%) had hypertension.93 
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Although reliable information on the causes of CKD in SSA is lacking, it is known that 
African Americans are at greater risk of CKD. The Human Heredity and Health in Africa 
(H3Africa) project is currently collecting data to enable better elucidation of these factors 
in SSA and understand genetic contributions to CKD and their interactions with other 
environmental factors.93 There is a genetic component to this increased risk, especially in 
people of West African descent where selection for the AP0l1 gene has been driven by 
protection from Trypanosomiasis.94 
 
In addition to a likely genetic predisposition and increased risk from poorly managed 
diabetes and hypertension, HIV also causes CKD. HIV and diabetes may act in synergy to 
worsen CKD and accelerate progression to cardiovascular disease.93 These factors 
combined with other underlying causes mean that the average age of onset of end stage 
renal disease in SSA is 20 years younger than in those in Western countries. For those 
who reach end stage renal disease and require renal replacement therapy the situation is 
troubling as services are unable to meet demand in most countries in SSA.94 
 
Worldwide, 1.8 million people received renal replacement therapy in 2004, and 5% of 
these were SSA.93 If 5-10% of people with CKD reached end stage renal disease, health 
systems in SSA countries would be overwhelmed94 could not afford to provide care.95 In 
2010, an estimated 50% of patients in SSA who needed renal replacement therapy due to 
underlying diabetes did not receive it – a number expected to double by 2030.92  
 
In SSA renal replacement therapy is often paid for out of pocket (at a cost of US $ 10-20, 
000 per year) – hence for most people, it is either unaffordable or leads to catastrophic 
expenditures for families. In university hospitals sampled in Nigeria and Kenya, less 
than 50% of those who needed dialysis were unable to pay.94 This percentage figure does 
not reflect those who never make it to a university hospital. For those who can afford to 
pay for end stage renal disease, mortality is likely to be high. Outcomes are poor, but 
gradually improving in patients receiving end stage renal disease globally96, but in SSA 
are worse than levels achieved in high-income countries.97 
 
Diabetic retinopathy in sub-Saharan Africa 
 
Diabetes causes visual impairment through early onset cataract formation and diabetic 
retinopathy. Globally, cataract and diabetic retinopathy are the second and sixth leading 
causes of visual impairment, respectively.98 The sight-threatening manifestations of 
diabetic retinopathy, proliferative retinopathy and maculopathy, are preventable and 
treatable before vision is lost.  
 
There are few community-based cross-sectional or cohort studies of diabetic retinopathy 
from SSA.99  A population based survey (n = 4,414) in Nakuru, Kenya, which reported a 
prevalence of diabetes of 6.5% in adults over 50 years, showed a prevalence of ‘any 
diabetic retinopathy’ and ‘severe non-proliferative diabetic retinopathy or proliferative 
diabetic retinopathy’ of 35.9% (95% CI: 29.7, 42.6) and 13.9% (95% CI: 10.0, 18.8), 
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respectively.100 A population-based study from Cape Town, South Africa, of visual loss 
using WHO methods identified DR as the cause of 8% of blindness and 11% of severe 
visual loss in people ≥50 years.101  
 
Currently few populations in SSA have access to systematic diabetic retinopathy 
screening and treatment.  Nascent case detection and treatment programmes, which 
serve as prototypes for how services might be structured, include regional-level outreach 
screening, services integrated into hospital diabetes clinics or eye departments.102 The 
Kilimanjaro Diabetic Programme is an integrated, clinic-based, mobile photographic 
retinal screening service in northern Tanzania.103 Diabetes clinics at 18 hospitals in the 
region are visited monthly.  By 2015, 5729 individuals were registered and 3463 (60·4%) 
had been screened.104 Only 40% of patients with referable eye disease attended their 
appointment at a tertiary referral centre providing laser, intravitreal injections and 
vitreoretinal surgery. This shortfall was attributed to limited understanding of diabetic 
retinopathy, logistics of attending referral appointments and the costs incurred.   
 
Another diabetic retinopathy screening programme is that organised by the 
Ophthalmologic Society of South Africa which emphasises its importance as a biomarker 
for systemic risk.105  And has recruited optometrists and general practitioners to increase 
access to screening opportunities close to the point of primary care. A systemic risk 
calculator serves as a counselling tool for patients and to determine follow-up.106 
 
Poorly resourced health services and poverty hinder diabetic retinopathy care in SSA, as 
do a lack of patient knowledge of diabetes and limited access to healthcare.  Referral 
pathways between diabetic clinics and ophthalmic services are underdeveloped and 
poorly organized. Indirect costs of attending hospital are high, and leading to delays 
when eye disease is not apparent prior to visual loss.  There are few ophthalmologists or 
opticians to perform opportunistic screening.107 Non-physician cadres such as 
ophthalmic clinical officers receive relatively little training in retinal disease, and eye 
services are overwhelmed by cataract, glaucoma, ocular trauma, infectious disease and 
paediatric ophthalmology.  Limited access to imaging and treatment infrastructure 
results in the under-development of skills in diabetic retinopathy management.   
 
Screening and care delivery programmes from industrialised countries are unlikely to be 
cost-effective in resource poor settings.  Digital photography with telemedicine links has 
the potential to deliver cost-effective, accessible screening to rural and remote 
populations. Fundus cameras remain prohibitively expensive. Validation studies are in 
progress for a number of portable fundus cameras.108,109 Automated grading of fundus 
photographs is used within established services including the Scottish National Diabetic 
Retinopathy Screening Programme and has been studied in Nakuru, Kenya.110 
 
Diabetic foot disease in sub-Saharan Africa 
 
Around 40-60% of all lower extremity non-traumatic amputations are performed in 
patients with diabetes.111 Amputations are not only devastating on their impact on people 
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with diabetes and their families, leading to loss of independence and livelihood; they are 
also very expensive. In SSA diabetic foot problems are associated with high morbidity 
and mortality.112,113 
 
Risk factors for diabetic foot ulceration (DFU) and amputations in SSA include: poor 
understanding of diabetes and its complications among healthcare professionals and 
patients, bare-foot walking, delays in seeking medical attention, poor diabetes control, 
and in some cases a preference by patients for alternative traditional therapies (faith or 
herbal healers) in the first instance. “Time is tissue” in the diabetic foot, and early 
recognition and treatment of DFU can prevent lower limb amputation and even death.114 
Unfortunately there is often a delay in accessing emergency foot care leading to poor foot 
outcomes in SSA management of a complex diabetic foot ulcer can cost more than 2 
years of average income for the patient and lead to catastrophic expenditures .112    
The loss of productivity caused by unemployment or sick leave during foot ulcer 
management is an added cost to the family, relatives, friends and communities.115  
 
Although well designed, community based studies are not available, published data from 
SSA suggest that diabetic peripheral neuropathy (DPN) is the most common 
complication of diabetes, occurring in in up to 75% of patients with diabetes116,117 as a 
result of poor glycaemic control.  In contrast to in high-income countries where 
peripheral vascular disease is closely associated with development of the diabetic foot, in 
SSA DPN remains the most common initiating factor for DFU. Yet, in most countries of 
SSA there is no foot/DPN screening for diabetic patients for risk stratification for DFU in 
order to provide preventive care.  Hence, it is not surprising that DFUs have become the 
most frequent cause of prolonged hospital admission in diabetic patients. 112  
 
Peripheral arterial disease is important in determining whether a DFU will heal. In SSA 
foot complications are generally neuropathic and/or infective in origin, but the pattern is 
changing as the prevalence of peripheral arterial disease is rapidly rising in the diabetic 
population. As compared with prevalence rates of less than 10% in the 1990s, recent 
studies show much higher rates of PAD between 20-54%.118,119,120  
 
A study of clinical outcome of patients with DFUs in Tanzania showed that 15% of 
diabetic admissions are due to DFU, 80% of which have occurred for the first time.112 
Amputations are frequent outcomes in DFUs and one-third of these are associated with 
neuro-ischemia and/or progressive infection.  The hospital mortality rate can be as high 
as 54% in those with severe DFUs (Wagner score >4) managed without surgery or 
amputation.112 Similar findings have been recorded in other parts of SSA. Sadly, some 
patients with severe DFUs discharge themselves from hospital against medical advice, 
putting themselves at increased risk of severe sepsis and death at home.121  
 
Unhygienic conditions and poverty may be associated with DFUs in SSA. Other risk 
factors for DFUs in SSA include walking barefoot or delay in seeking medical attention.   
Barefoot walking, a common practice in rural Africa is often related to low income but 
may be cultural as well. For patients living at or below poverty line, the purchase of 
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appropriate footwear might not be affordable, feasible or of high priority. Barefoot 
walking substantially increases the risk of DFU in those with DPN. Moreover, those with 
DPN who habitually sleep on the floor or outdoors may suffer painless rodent bites on 
the toes. DPN masks such injuries until the patient finally becomes symptomatic and 
presents with a DFU that has progressed to fulminating foot sepsis. Patients who do not 
have access to ongoing foot care, advice, or education are most at risk.  
 
In SSA patients often present to hospital only after the onset of gangrene or during 
stages of sepsis that may not respond to conventional supportive treatment with 
antimicrobials, intravenous fluids and insulin, resulting in progression to systemic 
infection and death.112 Initial antimicrobial therapeutic regimens are usually selected 
empirically and then modified as appropriate once the results of culture and 
antimicrobial susceptibility testing become available. Cultures of superficial swab 
specimens are not very useful since they tend to yield polymicrobial growth.  Deep tissue 
biopsy would yield more useful data, but many microbiology services in SSA do not have 
the resources to provide or maintain such routine culture services  
 
Infection, ulceration, and limb amputation are preventable through organised foot care 
programmes. A multidisciplinary approach with an emphasis on a comprehensive, 
preventive strategy, including patient and staff education, and multi-factorial treatment 
of DFUs such as the Step by Step Foot Project piloted and carried out in Tanzania and 
India showed that infection, ulceration, and limb amputation are potentially preventable 
through organized foot care programs including patient and staff education, joint 
medical and surgical management of foot ulcers, appropriate use of microbiology 
resources, and regular follow-up to reduce amputations by more than 50%.122  
It is not surprising, that foot infections are especially common where such services are 
especially scarce in SSA. Chiropody services, pivotal for foot care are non-existent in 
SSA. Consequently, lesions are either ignored or detected relatively late in the course of 
the infection after unsuccessful home therapy, such as soaking in hot water or 
application of unproven home remedies. Foot infections of this nature culminate in the 
onset of gangrene or infection with ensuing limb amputation or death from 
overwhelming sepsis. 
 
Epidemiological data on the prevalence of painful DPN in Africa is sparse and shows 
variations in prevalence rates.123 This is primarily because of using differing criteria of 
defining painful DPN and the assessment small and often unrepresentative samples of 
diabetic patients. The clinical features of painful DPN appear similar to that encountered 
outside Africa and results in poor quality of life, insomnia and depression. The four first-
line drugs include amitriptyline, gabapentin, duloxetine and pregabalin.  However, the 
availability and cost of a drug may be the determining factor for its use, which in most 
cases is amitriptyline.  
 
The most important intervention for the prevention of DFU is education of the patient 
about appropriate foot care. It is now well recognised that the establishment of foot 
clinics has resulted in the reduction of amputations. In low-income countries, the 
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inadequacy of foot services results in increase in the number of needless amputations. 
Preventative strategies for DFUs are virtually non-existent in many countries in SSA. 
Education is the most powerful preventive tool in low-income countries, and should be 
an integral part of prevention programs, and be simple and repetitive.124 
 
DFUs and amputations rates in patients with diabetes can be reduced by >50% by better 
education of patients and implementation of strategies, which are feasible in SSA 
countries: (i) regular inspection of foot and footwear at patient’s regular clinic visits (ii) 
preventive footwear prescribed for patients with high-risk feet (iii) implementation of a 
multidisciplinary approach to the management of foot ulcers in diabetes clinics (iv) early 
diagnosis of peripheral neuropathy and PAD (v) continuous follow-up of patients with 
previous foot ulcers and registration of amputation and foot ulcers for affected patients. 
 
HIV, tuberculosis and diabetes interaction in in sub-Saharan Africa 
 
HIV and TB are closely associated with diabetes. The association between diabetes and 
tuberculosis was known long before the discovery of insulin but the precise mechanisms 
underlying the alterations in macrophage function, cytokine production and T-cell 
subtypes in diabetes are not fully understood.125 Although research is ongoing to better 
elucidate the relationship.126  
 
Increasing prevalence of diabetes is hindering progress towards global targets for TB by 
2035.127 Pan and colleagues have found that with current rates of increase in prevalence 
of diabetes, in 13 countries studied by 2035, the cumulative reduction in tuberculosis 
incidence would be 8·8% and mortality would be 34·0%.128 They estimate that halting the 
increase in diabetes would avoid 6·0 million incident cases and 1·1 million tuberculosis 
deaths over 20 years. However, most of the evidence for relationships between TB and 
diabetes come from Asia, and African studies have reported an inconsistent association. 
No association between diabetes and tuberculosis was reported in Guinea Bissau despite 
an almost three-fold increased prevalence of diabetes relative to the general population 
in Nigeria.129,130,131 Hyperglycaemia may be transient at onset of TB, complicating 
evaluation of the true extent of the association with diabetes. Since HBA1c gives an 
assessment of glycaemia over a 2-3 month period it might be inferred that this, rather 
than shorter-term glucose measures, would perform better as a screening test. Although 
this was not shown in a study from Tanzania, where the strong association between TB 
and diabetes disappeared after - months of anti-TB therapy, regardless of the test used to 
diagnose diabetes.132  
 
Evidence that-pre-existing diabetes is associated with more severe symptoms and 
clinical presentation of TB is conflicting. People with both diabetes and TB do tend to be 
older and to have a higher BMI compared to TB cases without diabetes.  Radiologically, 
people with diabetes tend to have a higher occurrence of lower lobe involvement, a non-
segmental distribution, and multiple cavities within a tuberculous lesion. Of greater 
concern, diabetes and TB combined are associated with worse outcomes such as 
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increased risk of recurrence, delayed sputum clearance, and higher mortality. The same 
holds for drug sensitive and multi drug resistant TB.133  
 
Glycaemic control is frequently more difficult to achieve in patients with TB and diabetes 
than in diabetes alone, and TB may cause anorexia, weight loss and reduce physical 
activity as well as increasing insulin resistance and glucose levels, especially soon after 
TB is diagnosed. There may be drug-drug interactions. Rifampicin, for example, one of 
the cornerstones of TB regimens, reduces the efficacy of many sulfonylureas because it 
induces CYP2CP in the liver and lowers the area under the curve of these drugs by 22-
70%. INH may cause peripheral neuropathy, which may be confused with that due to 
diabetes.134  
 
The pathophysiological basis for the association between diabetes and HIV and this 
interaction leading to cardiovascular disease is not clear.  It is thought that the chronic 
inflammatory state induced by HIV contributes to insulin resistance, which may persist 
despite exposure to ART. In addition to this, some of the older protease inhibitors and 
nucleoside reverse transcriptase inhibitors induce dysregulation of mitochondrial 
function leading to insulin resistance and diabetes.134  
   
The reported incidence and prevalence of diabetes in people living with HIV is highly 
variable, most likely due to factors such as diabetes prevalence in the general population, 
diagnostic method used, sample sizes, duration of follow up, year of the study and the 
use of specific antiretrovirals.135 Agents such as stavudine and zidovudine are known to 
be associated with diabetes, and efavirenz, the preferred non-nucleoside reverse 
transcriptase inhibitor (NNRTI) for first line ART in low and middle income countries, 
has since been associated with a modest increased risk of developing diabetes (Hazard 
ratio 1.27 (95% CI 1.10 to 1.46) compared to nevirapine, after controlling for multiple 
confounders in a large South African cohort study with 113,297 patient-years of follow-
up on first line ART.136 Although stavudine has been withdrawn from most first line 
regimens long term therapy with efavarinz and zidovudine may require regular screening 
for diabetes. Ideally, this could be in the form of a two-step process involving 
administration of a validated diabetes risk score followed by a blood test in those with a 
high score. Unfortunately, there is no validated risk score for diabetes in Africa per se, let 
alone in people who are HIV infected.137 
 
There is sparse information on the prevalence of diabetes in people with comorbid HIV 
and, or TB in Africa.  Current evidence suggests that diabetes prevalence is lower in 
individuals with both TB and HIV compared to those with either disease alone, although 
that may change given the rising numbers of people with diabetes in SSA, the earlier 
introduction of ART and the ageing of the patients with HIV receiving ART.138,139  
 
Many unresolved issues remain, however. These include understanding attributable risk 
of diabetes and HIV for tuberculosis in a high-risk HIV setting.  We still need to identify 
the most reliable and cost effective screening method for diabetes in HIV and/or TB 
infected persons and visa verse, and when the screening should take place. Beyond this, 
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there is the need to achieve optimal glycaemic control in those identified as suffering 
from co-morbidity, and to establish whether management of hyperglycaemia, and to 
what level, even in the short term, alters outcome. In Africa, sulfonylureas and 
metformin are the backbone of therapy for type 2 diabetes. Given that access to self- 
blood glucose monitoring and insulin is frequently problematic even for children with 
type 1 diabetes in most SSA countries, the use of intensive insulin therapy in comorbid 
diabetes and TB is likely to be limited to tertiary or specialised centres. 
  
Cardiovascular disease, hypertension and diabetes in sub-Saharan Africa  
 
The relationship between diabetes, hypertension, hyperlipidaemia, and the subsequent 
increased risk on cardiovascular disease has been reported extensively elsewhere.140 
Most of this literature, however, pertains to high-income countries, and very little is 
known about either the prevalence of co-morbid risk factors and related CVD, or how 
these conditions interact in an African setting.141,142 Although diabetes and obesity 
contribute to cardiovascular morbidity and mortality, hypertension (often found in 
association with diabetes) is the largest contributor to cardiovascular deaths globally.143 
In low-income and middle-income countries, the epidemiological transition is 
characterized by a gradient in blood pressure from rural to semi-urban and 
communities,144 and prevention is the key cost-effective intervention.145 Obesity and 
hypertension are the most common cardiovascular risk factors in SSA where access to 
healthcare, cardiovascular screening and treatment are a constant challenge.146  
 
The prevalence of high blood pressure has increased rapidly over the past two to three 
decades.  It is estimated that 150 million Africans will be treated for hypertension by 
2025 compared to 80 million in 2010, an increase attributed to increased tobacco use, 
excessive alcohol consumption, reduced physical activity and adoption of "Western" 
diets and other features of the economic transition. According to the WHO STEPS 
surveys conducted in the region, the prevalence of high blood pressure ranges from 
19.3% in Eritrea to 39.6% in Seychelles.147 
 
Low public awareness and inadequate control and treatment of hypertension are major 
public health concerns in Africa. Recent systematic review of data from 33 surveys 
involving over 110, 000 participants in SSA found a pooled prevalence of hypertension of 
30%, but only 27% of people with hypertension were aware of their status before the 
surveys, only 18% were on treatment and only 7% had acceptably controlled blood 
pressure.148 Another major problem is access to and affordability of drugs, since out of 
pocket expenses are the main source of medications and treatment.  There are thus many 
barriers to effective control of blood pressures despite the availability of cost effective 
medications. These include: poor implementation of screening programs, lack of access 
to affordable medicines and commodities, and poor knowledge amongst patients and 
health care providers of the need for adherence, monitoring and early identification of 
complications. 
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We discuss next how health systems in SSA have responded to the growing burden of 
diabetes and examine in selected countries the readiness of health systems and key 
functions in managing diabetes.149 
 
 
Health system responses to diabetes in sub-Saharan Africa 
 
The majority of research on diabetes in SSA has generally focused on epidemiology and 
clinical presentation, with few studies that explored health systems, but these studies 
were limited in scale and scope.150  
 
We used published studies and analysis of surveys to explore health system responses to 
the rising burden of diabetes in SSA. We used a health systems framework to guide our 
analysis and systematically examined repose to diabetes in key health systems functions 
of organization and governance, financing, resource management, and service delivery151.  
 
Organization and governance of diabetes in health systems of sub-Saharan 
Africa  
 
The state capacity, organizational and governance structures and institutional strength 
of health systems vary across SSA. By 2010, 42 of the 45 countries of SSA had reported 
having a unit or department within their ministries of health with responsibility for 
NCDs.152 However, just seven countries had a national operational policy, strategy, or 
plan for diabetes, lower than other NCDs (Figure 4) 
 
Figure 4 
 
A majority of countries in each World Bank income group had plans for two or fewer of 
the NCDs and NCD risk factors (Figure 5). 
 
Figure 5 
   
The availability and the stage of implementation of guidelines, protocols, or standards 
for diabetes management varied across countries. Just four countries across SSA had 
guidelines, protocols or standards that were fully implemented  (Figure 6). 
 
Figure 6 
 
Financing of diabetes in sub-Saharan Africa 
 
In 2001, African nations adopted the Abuja Declaration, pledging to allocate at least 15% 
of their national annual budgets to health spending.153  Yet, by 2013 only seven countries 
in SSA – the Central African Republic, Ethiopia, Malawi, Rwanda, Swaziland, Togo and 
Uganda – had reached that target. 
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In 2010, average health expenditure per capita was $135.154 In 2012, total health 
expenditure in SSA as a proportion of GDP average 6.3%, ranging from 6.6% in the 23 
low income countries, 6.1% in the three low middle-income countries and 5.5 in the five 
upper middle-income and one high income country. 155  In the same year, average public 
spending on health accounted for 49 percent of total health spending.156  
 
In 2012, the average level of out of pocket expenditures as a proportion of total 
expenditures on health was 36 percent, ranging from 76 percent in Sierra Leone to two 
percent in the Seychelles.157 In 12 countries, out-of-pocket expenditure comprised more 
than 50% of total health expenditure – vastly exceeding public health spending. 158 
External funding ranged between 46 percent in the Gambia to one percent in Equatorial 
Guinea, with an average of 25 percent.159  
 
To increase health financing for NCDs, several countries such as Cameroon, Botswana 
and Seychelles, have introduced earmarked taxation to influence health behaviours, with 
revenues channelled to health promotion activities. Others have launched reforms to 
increase public funding for health systems and to achieve universal health coverage, but 
large informal sectors hinder effective tax collection to invest in health systems.160  
 
Low levels of public funding, low income levels and high out-of-pocket expenditures 
have adversely affected the uptake and provision of care for diabetes patients, increasing 
the likelihood of long-term complications.161,162 In Malawi, for example, families spent 22 
percent of their monthly per capita budget on out-of-pocket expenditures related to 
NCDs.163 For patients with Type 1-diabetes high out of expenditures have and 
unaffordability of care has grave consequences, with high mortality levels among 
patients, as regular insulin injections are not always affordable.164  
 
There is major variation in health system spending on diabetes in SSA. According to the 
International Diabetes Federation (which estimates costs based on the cost to the 
patient, as well as the cost to the health system), in US$ purchasing power parity, using 
2013 World Bank country income groups, the average cost was $67.4 in low-income 
countries, $201.1 in low middle-income countries, $683.2 in upper middle-income 
countries and $2,036 in the one high-income country.165,166  
 
Resource management in health systems for tackling diabetes in sub-
Saharan Africa 
 
Sub-Saharan Africa has an acute shortage of healthcare professionals: the WHO African 
Region accounts for 25 percent of the current global health workforce shortage, expected 
to rise to 34 percent by 2035 as a result of population growth in Africa.167 The shortage of 
health workers, exacerbated by emigration168, has constrained achievement of 
Millennium Development Goals.169,170 
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There is shortage of medical graduates (more than half of the countries in SSA have only 
one medical school, and 11 countries have no medical school)171 and nurses, whose level 
of training and skills vary greatly across countries172. More than half of SSA countries 
have a category of non-physician clinician (providers who complete an average of about 
three-years of post-secondary clinical training)173 and many countries such as Ethiopia 
and Malawi have successfully used community health workers (CHW) to scale up HIV, 
tuberculosis, malaria and other essential services.174,175  
 
Service delivery for diabetes in in sub-Saharan Africa 
 
To inform the 2010 Global Status Report on Noncommunicable Diseases176, WHO led 
several country-level surveys to assess national capacity of countries in prevention and 
control of NCDs. The WHO Service Availability and Readiness Assessment (SARA) 
survey, which measured the availability of diagnostic tools, essential medications and 
trained staff at the facility level for series of tracer conditions, including diabetes and 
cardiovascular disease, was applied in eight SSA countries.177 The SARA questionnaire, 
reference manual, implementation guide and completed reports, but not the study data, 
are available on the WHO website for countries wishing to conduct a survey.178  
 
The findings from the country-level SARA reports indicate that there are major gaps in 
front-line service delivery.  In the eight study countries, less than one half of facilities 
offered diabetes management.179 Of the facilities that did offer diabetes services, only 40 
to 60 percent were ready to provide diabetes services (Table 2).  
 
Table 2 
 
With the exception of Uganda, only about one-third of facilities offering diabetes services 
had guidelines for treatment, and one-third or fewer had at least one trained staff.179 The 
discrepancy between trained staff and availability of diagnostic supplies and medication 
is concerning as it is not clear how supplies and medications are being used in the 
absence of staff with formal training in diabetes care.179 The availability of blood glucose 
testing ranged from 14 percent in Burkina Faso to 80 percent in Uganda – although only 
31 percent of Uganda sites reported the availability of trained staff.  
 
Availability and access to medicines for diabetes in sub-Saharan Africa 
 
The availability of oral hypoglycaemic medicines, such as metformin and glibenclamide, 
was as low as six percent in Burkina Faso, and as high as 70 percent in Zambia, although 
once again, Zambia reported trained staff at only 20 percent of facilities. Insulin was 
available in fewer than half of facilities in all countries.179 A separate study of access to 
treatment and medicines in Mozambique, Mali, and Zambia corroborated the findings of 
SARA surveys in difficulty accessing drugs for control of diabetes.179  
 
According to WHO, essential medicines for diabetes are not available in all SSA 
countries: oral medicines for as metformin and glibenclamide are available in 29 and 35 
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countries respectively, insulin in 32 countries and aspirin (acetyl salicylic acid – ASA 
100) tablets used for primary prevention of cardiovascular disease in patients with 
diabetes is available in 41 of the 45 countries180 (Figure 7). 
 
Figure 7 
 
An integral part of the WHO Global Action Plan (GAP) for the Prevention and Control of 
Noncommunicable Diseases 2013-2020 (NCD GAP) is the target of 80% availability of 
the affordable basic technologies and essential medicines, including generic drugs, 
required to treat major NCDs in both public and private facilities.181 This target is 
essential to enable countries to meet the 25% relative reduction in premature mortality 
from NCDs by 2025, as defined by the WHO in the NCD GAP. However, studies reveal 
access challenges due to a lack of availability and affordability of insulin with median 
availability of insulin in the public sector of 75% in the public sector (5 countries) and 
46% in the private sector (6 countries).182 Availability and affordability of diabetes 
medicines in also a challenge in SSA.183,184,185,186,187  
 
A recent study which used from the World Trade Organization found that only 16.7% of 
SSA countries bought insulin every year during the period 2004-2013, but 29.2% of 
countries did not buy insulin over this period and 38% of countries were reliant on less 
than one supplier for their insulin.188  
 
WHO SARA survey reports provide countrywide assessment on the availability of 
insulin, metformin and glibenclamide for 9 countries in SSA. For insulin median overall 
availability was found to be 13% of facilities surveyed (Range: 3%-39%). For insulin 
median availability decreased at lower levels of the health system, was actually more 
available in rural versus urban areas (median of 12% versus 7%) and had higher in the 
private contrasted with the public sector (median of 11% versus 3%). Metformin had a 
higher overall median availability in comparison to insulin of 22% (Range: 2% to 57%). 
Similar trends as with insulin were found: decreasing availability at lower levels of the 
health system; higher availability in rural areas; and higher availability in the private 
sector. Glibenclamide shows similar trends except that for this medicine the availability 
is higher in urban versus rural areas.189,190,191,192,193,194,195,196,197 These data are presented in 
Table 3. 
 
Table 3 
 
These data clearly show that the countries studied are far from achieving the 80% target 
included in the GAP. However, availability varied with regards to level of the health 
system, urban versus rural, and public versus private – suggesting disparities.  
 
Analysis of the prices of diabetes medicines in SSA can be undertaken using data from 
Management Sciences for Health (MSH), which provides the international reference 
prices for many medicines. 198  The prices quoted by MSH are from tenders from 
ministries of health, and represent the price of the medicine without any add-on costs at 
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the point of entry to a given country. Analysis of data from 1996 to 2013 The median 
price for insulin (10ml 100IU/ml vial) in SSA (8 countries) is US$ 7.15 (Range: US$ 1.52 
to US$ 17.58) at constant 2015 prices.199 For metformin (500mg; 10 countries), gliclazide 
(80mg; 4 countries) and glibenclamide (5mg; 13 countries) the median prices are 
respectively US$ 0.018 (Range: US$ 0.002 to US$ 3.304), US$ 0.023 (Range: US$ 
0.012 to US$ 0.060) and US$ 0.004 (Range: US$ 0.0004 to US$ US$ 0.032). Using 
Defined Daily Dosage (DDD)200 the yearly treatment costs are presented in Table 4. 
 
Table 4 
 
Table 4 shows that treatment with insulin presents a significantly higher cost for 
individuals versus the use of oral medicines for diabetes. The prices presented in Table 4 
do not take into account of mark-ups, such as value added sales tax, local taxes, 
international purchasing verification tax, insurance, defence levy, overheads mark-up, 
bank fees, fee for import declaration form, port clearance, importer margin, handling 
cost, wholesale mark-up, retail mark-up, health facility mark-up, dispensing charge or 
other mark-ups within the system. Although data are lacking for these mark-ups, 
specifically for insulin, for other medicines the additional cost of these have been found 
to range from 18.4% to 94.4% of the price of the medicine.201  
 
These add-on costs as well as subsidies within health systems mean that there are many 
factors influencing the affordability of insulin, the price of for which can vary 
substantially.180 For example data from 4 studies in 3 African countries suggest that in 
2003 in Mozambique and 2004 in Mali between the central government and facilities 
there was an increase in price to recuperate some of the storage and transportation 
costs.180 This increase in price was not observed in Zambia and in Mozambique in 
2009.180,202 In two studies from Mozambique and in Zambia the price between the 
facility and the patient was subsidised, whereas in Mali there was an additional mark-up 
meaning that between the government purchase price and patient purchase price there 
was a 47% price increase. In order to present different prices of insulin different data 
sources were combined to show the median price at different levels of the health system 
at 2015 prices180, 199,202,203 (Figure 8). 
 
Figure 8 
 
In comparing the MSH prices to those obtained by different ministries of health Figure 8 
shows that many countries are purchasing insulin at the best price possible, but there are 
still some outliers. For patients in the public sector in some countries insulin is provided 
for free or subsidised, whereas in others the price can be quite high. That said these 
prices are relatively low in comparison to prices in the private sector, highlighting the 
importance of ensuring proper availability in the public sector. Clearly some of the prices 
presented in Figure 8 are not affordable to individuals in these countries, for example 
US$ 10.88 in the public sector in Mali or US$ 50.57 in the private sector in Ethiopia.199  
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Data from WHO/HAI found that in terms of days wages people in some countries in SSA 
had to pay between 0.9 to 6.7 days of wages to be able to pay for their treatment (Figure 
9).186 Based on that affordability for the WHO/HAI approach is that the lowest paid 
government worker should only pay one-day’s wage for treatment. The data presented in 
Figure 9 suggests only glibenclamide in Ethiopia is affordable. 
 
Figure 9 
  
However, in SSA many individuals do not work in the formal sector, and therefore 
measuring affordability in terms of the wage of the lowest paid government worker does 
not take into account that most people do not make a monthly wage and live on less than 
US$ 1.90 and US$ 3.10 per day.204 Comparing annual cost of diabetes medicines (Table 
4) and daily costs of the different diabetes treatments with different thresholds of 
poverty using daily income show that daily drug costs represent from 0.5% to 15.1% of 
income for someone living on US$ 1.90 per day (Table 4). These costs correspond to the 
prices paid when a ministry of health has purchased medicines, and not the prices 
individuals might pay when purchasing these drugs in the public or private sector.  
 
Affordability is not only important for the individual, but also for the health system. For 
some countries in SSA it has been found that depending on the price of insulin the cost 
to the health system can vary from 0.2% of total GDP in South Africa to 13.4% in Malawi 
for their total insulin needs.205  
 
The costs of medicines are significant, but are only one part of the overall cost which 
include the cost of delivering medicines which require a well-functioning health system 
to ensure proper diabetes care including: trained health professionals, organised centres 
for care, diagnostic tools, data collection, national policies, an active diabetes 
association, patient education, measures to improve adherence and prevention 
measures.206  
 
Health service delivery for diabetes in sub-Saharan Africa: analysis of 
Service Delivery Indicator Surveys 
 
To better understand service delivery gaps in diabetes care we were able to receive the 
Service Delivery Indicator (SDI) surveys conducted in six SSA countries by the World 
Bank in cooperation with the African Economic Research Consortium, and the African 
Development Bank in SSA.207  
 
The SDI surveys include primary health facility level data on expenditures, provider 
effort (absence rate, caseload per provider), provider knowledge and ability (diagnostic 
accuracy, adherence to clinical guidelines, and management of maternal and neonatal 
complications), and inputs (availability of supplies, equipment, and drugs). Diagnostic 
accuracy is measured through patient case simulations (vignettes) for the following 
seven tracers: (i) malaria with anaemia; (ii) diarrhoea with severe dehydration; (iii) 
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pneumonia; (iv) diabetes; (v) pulmonary tuberculosis; (vi) postpartum haemorrhage; 
and (vii) neonatal asphyxia.  
 
The SDI surveys are complementary to the surveys that focus on the availability of 
resources and provide valuable data beyond those provided by WHO SARA surveys, 
which are designed to capture availability of resources in facilities for management of 
NCDs, including diabetes, to ascertain health system readiness for service provision.208 
(Panel 1) Hence, our analysis of SDI surveys builds on the analysis of SARA surveys to 
broaden and deepen our understanding of service delivery as well as the quality of these 
the care provided management of diabetes by providing insights into the knowledge 
ability and effort of providers (technical quality) as well as measures on the availability of 
key inputs, such as drugs, equipment and infrastructure (structural quality).209 
 
The first rounds of SDI surveys in Senegal and Tanzania (2011) did not include a diabetes 
vignette and were excluded from our analysis. The total sample consists of Kenya (2012), 
Mozambique (2014), Nigeria (2013), Tanzania (2014), Togo (2013) and Uganda (2013).   
 
Panel 1: World Bank Service Delivery Indicators survey: methodology 
The surveys use a multi-stage, cluster sampling strategy, which allows for disaggregation 
by geographic location (rural and urban), by provider type (public and private non-
profit) and facility type (e.g. dispensaries/health posts, health centres, and first level 
hospitals).  
 
The tracer conditions for the patient simulation vignettes were chosen based on the 
disease burden among children and adults, and whether the condition could be 
effectively presented during the simulation in order to assess provider’s ability to give the 
correct diagnosis. During the vignette, one of the fieldworkers acts as a case study patient 
and presents the symptoms to the clinician. The symptoms are carefully scripted to allow 
comparability across providers and countries. The clinician is aware of the case 
simulation but is asked to proceed as if the fieldworker is a real patient. The other 
enumerator acts as the observer. For the physical examination and laboratory 
components of the visit, the provider is told to ask questions rather than performing the 
actual task. The patient responds verbally with the appropriate measures. Up to ten 
health workers who typically conduct outpatient consultations are randomly selected to 
assess the patient simulation. If there are fewer than ten health workers providing 
outpatient care at the facility, all providers are interviewed.  
 
The vignettes offer several advantages. Since all clinicians are presented with the same 
case study patients, we are able to standardize the case mix and severity of the conditions 
to allow for comparability across providers. The ethical approval process is relatively 
simple given than no patients are observed, and the choice of tracer conditions is not 
dependent on the patient’s ability to mimic certain symptoms. As discussed in the 
introduction, however, performance on vignettes is likely to represent the upper bound 
of true clinical ability and is likely to be higher than the average level of care available to 
real patients210,211 
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Provider’s Ability 
Provider’s ability is measured using two indicators: diagnostic accuracy and process 
quality. First, we examine whether the provider was able to diagnose diabetes correctly 
during the patient case simulation. We create a binary variable equal to 1 if the provider 
was able to diagnose diabetes correctly and 0 otherwise. Secondly, we assess process 
quality for diabetes care by investigating the degree to which the provider adhered to 
clinical guidelines during the patient case simulation. The clinical guideline score is 
calculated as a share of relevant tasks performed in four domains: symptoms, patient 
history, physical exam, and laboratory diagnostics. All components are given equal 
weight. Due to the standardization of the vignettes, we are able to compare diagnostic 
accuracy and process quality across and within countries.  
 
Covariates 
In our analysis we control for both provider and facility level characteristics that could 
independently predict quality of care. At the provider-level, these include covariates for 
gender and cadre of provider.   
 
Facility-level characteristics include facility type (dispensary/health clinic, health centre, 
or district hospital), location (rural, semi-urban, or urban), and ownership (private or 
public). In addition, we also construct an equipment index, calculated as the unweighted 
average of available and functioning essential equipment (sphygmomanometer, adult 
weighing scale, thermometer, and stethoscope). In Tanzania and Uganda, the surveys 
also collected data on whether facilities had a glucometer available. We control for the 
presence of a glucometer separately for these two countries. Data on whether providers 
received any diabetes or NCD-related training are not available.  
 
Statistical analysis 
We calculated descriptive statistics of the sample of health workers for all variables of 
interest, presenting the proportions for binary variables and mean and standard 
deviation (SD) for continuous covariates. We separately examined the associations 
between diagnostic accuracy and the clinical guideline score with observed provider and 
facility-level characteristics. For diagnostic accuracy, we used a logistic regression since 
the variable was binary (equal to 1 if provider correctly diagnosed diabetes, 0 otherwise).  
 
We used ordinary least squares (OLS) regression to examine the association between the 
clinical guideline score and covariates of interest. To normalize the distribution, we log 
transformed the clinical guideline score. All analyses were conducted in Stata 14.0 
(StataCorp, College Station, Texas).   
 
We provide a summary of the provider characteristics in Table 5. The total sample 
consisted of 7,414 providers, with the largest number of providers in the sample coming 
from Nigeria. The sampled providers are on average five years younger in Kenya and 
Uganda compared to the other countries. With the exception of Tanzania, nurses, 
midwives, and community health workers represented more than half of the sampled 
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providers. In Tanzania, 74% of the sample consisted of physicians, medical or clinical 
officers. In Nigeria, physicians represented only 9% of the sample, while nurses, 
midwives, and community health workers represented 81% (largely community health 
workers). In Kenya, Nigeria and Uganda, the majority of sampled providers were female.  
 
Table 5 
 
Descriptive statistics in Table 5 shows that higher shares of providers in all countries 
were employed at lower level facilities (dispensaries/health clinics or health centres) and 
were primarily located in rural areas. On average, providers worked at facilities with a 
high equipment index, suggesting that they had access to a thermometer, adult weighing 
scale, sphygmomanometer, and stethoscope. In Nigeria and Uganda, however, more 
than a third of providers did not have access to all four pieces of equipment.   
 
Less than 50% of the sampled providers in all countries were able to accurately diagnose 
diabetes, with the exception of Kenya where 82% of providers gave the correct diagnosis. 
As shown in Error! Reference source not found.4, compared to other tracer 
conditions simulated in the vignettes, diabetes was the second least diagnosed condition 
(after diarrhoea with severe dehydration). Conversely, more than 80% of providers were 
able to diagnose tuberculosis and neonatal asphyxia, with the share as high as 97% and 
91% in Kenya and Tanzania, respectively. Only 6% of the sample was able to diagnose all 
seven conditions (six in the case of Togo).  The share was highest in Kenya, where almost 
27% of the surveyed providers correctly diagnosed all conditions presented during the 
patient simulation. On the contrary, only 1% of the surveyed providers in Mozambique 
were able to diagnose all cases. 
 
Figure 10 
 
While the average clinical guideline score was less than 30 percent, we observed a wide 
range of performance scores with some providers performing all the necessary tasks 
(Error! Reference source not found.11).  
 
Figure 11 
 
Providers scored consistently higher in the laboratory domain (Figure 12), indicating 
that they would order the appropriate laboratory diagnostics to diagnose the patient. 
Conversely, with the exception of Tanzania, providers scored lowest in the patient 
history domain – asking less than 20 percent of the appropriate questions. 
 
Figure 12 
 
The majority of providers who correctly diagnosed diabetes could not prescribe the 
appropriate treatment and indicated that they would refer the patient for a follow up 
visit at a specialist diabetic clinic or higher level facility (Figure 13). In Tanzania, 
however, 80 percent of providers indicated that they would prescribe oral 
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hypoglycaemic, with 49 percent of providers referring patients to more specialized 
facilities. 
 
Figure 13 
 
Table 6 presents the logistic regression results of the factors associated with a provider’s 
ability to diagnose diabetes. Female providers had significantly lower odds of correctly 
diagnosing diabetes in Kenya (0.81 OR; 0.37 - 0.99 95% CI) and Nigeria (0.8 OR; 0.68 - 
0.94 95% CI). Relative to the highest cadre category (physicians, medical or clinical 
officers), lower cadres had significantly lower odds of diagnosing diabetes in all countries 
except for Mozambique, where we did not find statistically significant differences.  
 
Table 6  
 
Table 6 shows that providers employed at district hospitals in Mozambique (2.11 OR; 
1.25 - 3.56 95% CI), Nigeria (2.25 OR; 1.53 - 3.32 95% CI), and Tanzania (2.26 OR; 1.21 - 
4.20 95% CI), were significantly more likely to diagnose diabetes. Location was only a 
significant predictor in Nigeria and Togo, with providers in urban areas having higher 
odds of diagnosing diabetes than those in rural areas. We did not find a statistically 
significant relationship between the ability of providers to diagnose diabetes and 
whether the facility was public (Table 6). Interestingly, in Kenya, Nigeria, and Uganda, a 
higher equipment index was found to significantly increase the odds of correctly 
diagnosing diabetes. As mentioned earlier, the variation in the equipment index was 
quite low with the majority of providers having access to the basic equipment 
(particularly in Kenya), thus the significant odds ratios suggest that ensuring universal 
availability of basic equipment could substantially improve diagnostic accuracy.   
 
Table 7 presents the OLS regression results of the factors associated with higher clinical 
guideline scores. The dependent variable is the log transformed clinical guideline score. 
The results are consistent with the findings related to diagnostic accuracy. Lower cadre 
providers are less likely to have higher clinical guideline scores. Nurses, midwives, and 
community health workers are found to have 5-7% lower clinical guideline score than 
physicians, medical and clinical officers. In Mozambique, Nigeria, and Tanzania, 
providers at district hospitals are found to have a 6-9 % higher clinical guideline score 
than providers at the lowest level facilities. The equipment index is also positively 
associated with the clinical guideline score in Kenya, Nigeria, and Uganda. 
 
Table 7 
 
Health system responsiveness to diabetes: implications for sustainable 
health systems in sub-Saharan Africa 
 
The examination of reports from WHO SARA surveys undertaken in nine countries, and 
analysis of World Bank Service Delivery Indicator surveys in six countries reveals that 
health systems of the countries examined are not yet ready for delivering effective health 
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services for diabetes patients. However, a comprehensive understanding of health 
systems readiness for managing diabetes in SSA is constrained by a lack of data, 
especially how resource and service gaps affect demand, and how the interaction of 
supply-side gaps and demand-side dynamics translate to unmet need. We provide in the 
next section new analysis that uses surveys in 10 countries of SSA to examine the nature 
and extent of unmet need at each critical stage of the care process.  
 
Analysis of Cascade of Care and Unmet Need for 
diabetes in sub-Saharan Africa 
 
The examination of reports of SARA surveys and analysis of Service Delivery Indicator 
surveys in Section 3 of the commission report lay bare the consequences of underfunded 
and weak health systems and years of suboptimal investments in human resources212, 
which have led to large resource gaps for diabetes care in SSA.  
 
Limited availability of diabetes services means that persons affected by diabetes in SSA 
consume less care than those in Europe, China and North America. However, when 
patients with diabetes are able to access healthcare services, they consume more 
healthcare services at all levels of care than their peers who do not have diabetes – as a 
study in Cameroon, Mali, South Africa and Tanzania indicates, where patients with 
diabetes had 6.27 times more inpatient admissions, 12.95 times more inpatient days, and 
7.54 times more outpatient visits per person per year than a matched comparison group 
of non-diabetics.213 However, extant research does not provide detailed insights or 
quantify the extent of unmet need for diabetes services in SSA.  
 
Understanding how health systems resources are allocated to diabetes care, how these 
resources are used and how providers provide care provides valuable insights into the 
response to the diabetes burden. It is important, however to understand better the 
consequences of the health system response, in order to ascertain if and how the demand 
for diabetes care is being met, and where gaps exist.  
 
Analysis of cascade of care for diabetes in sub-Saharan African 
health systems  
 
One innovative analytic approach to assessing health system performance for single 
diseases is the construction of a cascade of care. The cascade of care has been used to 
monitor progress toward coverage goals for populations affected by HIV/AIDS.214,215 This 
method typically involves a quantitative depiction of the step-wise care system for the 
population affected by a disease of interest, including screening, diagnosis, linkage to 
treatment programmes, adherence to treatment and finally achievement and 
maintenance of control.  
 
The strengths of the cascade of care analysis include the opportunity to identify where in 
the continuum of care the areas where there is unmet need and where the greatest losses 
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occur. The cascade approach depicts the product of the interaction and dynamics 
between health system responses and demand at each step of the care continuum – in 
effect, showing the process by which inputs translate to outputs and outcomes, and 
where attrition in care occurs. This in turn can help to facilitate effective, evidence-based 
targeting of programmes and policies to address the demonstrated gaps. In addition, 
cascades can be used to monitor responses to new interventions, programmes or 
policies, assess progress toward achieving public health goals and to share best practices 
(and challenges) among policy makers and providers.  
 
The cascade of care approach is being applied in understanding better management of 
chronic non-communicable diseases such as diabetes, by using administrative or survey 
data. For example, in one study in the United States, data from the National Health and 
Nutrition Examination Survey (NHANES) from 2007 to 2012 was used to construct a 
diabetes cascade of care for the US to show that nearly one third of patients with diabetes 
were unaware of their diagnosis and that those who remained undiagnosed were less 
likely to achieve health targets for multiple chronic diseases.216 
 
We used the cascade of care approach, drawing on population-based surveys in selected 
SSA countries that included diabetes to assess the care for diabetes and the extent of 
disease control. The cascades were constructed based on individual-level data from 10 
surveys in 10 countries in SSA countries that were conducted between 2005 and 2013. 
The World Health Organization’s STEPS Survey was available for 8 countries. The 
STEPS Survey is a standardised approach to collecting data about NCDs among adults 
aged 25-64 years in WHO member countries (Appendix). In brief, the STEPS Surveys 
include collection of demographic data (STEP 1), physical measurements such as blood 
pressure and BMI (STEP 2) as well as biochemical measurements, including fasting 
plasma glucose (STEP 3).217,218 Further details about the STEPS instrument are provided 
elsewhere.4 Given that a standardised approach is used across all countries, data from 
the STEPS Surveys can be used to compare epidemiology and health system performance 
across countries. STEPS Survey data were available for the following countries: Benin, 
Comoros, Guinea, Liberia, Mozambique, Seychelles, Tanzania and Togo. 
 
We supplemented the data from the eight STEPS with information from the 
Demographic and Health Survey for Namibia (2013), which as with STEPS surveys 
includes both fasting plasma glucose measurement and self-reported data on access to 
diagnosis and treatment for diabetes.219 For South Africa, we utilized the South Africa 
Nutrition and Health Examination Survey (SANHANES), a nationally representative 
cross-sectional health and nutrition study that was led by the South African Human 
Sciences Research Council.220 Together, the STEPS, DHS and SANHANES surveys 
represented 39,062 individuals across 10 countries over the period from 2004-2014. 
 
Definitions and constructing the diabetes care cascade 
 
Diabetes was defined based on the current WHO and American Diabetes Association 
diagnostic criteria as any one of the following: a fasting plasma glucose greater than or 
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equal to 7.0 mmol/l (126mg/dl); a 2–hour plasma glucose ≥ 11.1mmol/l (200mg/dl) or; 
a HbA1c measurement ≥ 6.5%.221 This definition represents the current gold-standard 
clinical practice guidelines that are being used internationally. Those reporting use of 
medication for diabetes were also classified as diabetic irrespective of the biomarker 
values. Respondents who self-reported a diagnosis of diabetes but were not on 
medication and lacked the criteria indicated above were not classified as diabetic. In 
addition, we quantified met need for four different metrics of diabetes care in the 
diabetic population: ever receiving a blood glucose measurement as a measure of 
diagnosis; ever having been told about the diagnosis of diabetes as a measure of 
awareness of diagnosis; receipt of any advice from a healthcare provider to lose weight or 
exercise (hereafter “any advice’) and use of either oral medications or insulin, for treating 
diabetes (hereafter “any medication”). 
 
Using these metrics, we constructed a diabetes care cascade for each of the 10 countries. 
This cascade, created using individual data, shows the percent of the total diabetic 
population that self-reported reaching each subsequent step in the care process, 
conditional on having reached the previous step. The first stage in our cascade is ever 
having had a blood glucose measurement (prior to the STEPS or other Survey on which 
the diagnosis was made) as an indicator of having had an appropriate diagnostic test for 
diabetes. Second, among those who had received this test, we then quantified the 
percentage of all diabetic patients who had been informed about their diabetes diagnosis 
by any healthcare provider as a measure of awareness of diagnosis. Third, among those 
who had received a diagnostic test and were aware of their diagnosis, we calculated the 
percentage of the total diabetic population who then received any advice regarding 
lifestyle modification and finally, among that group, the percentage that had received 
oral medications or insulin for diabetes control.  
 
The diabetes care cascade by country is displayed in Figure 14. The first step in the 
cascade is receipt of a diagnostic test, specifically a blood glucose measurement. This 
initial diagnostic test was associated with the largest loss to care across all countries, 
with an average of 40% and ranging from 23% to 81%. (Figure 14)  
 
Figure 14 
 
Second, among the group who self-reported having received glucose measurement, the 
cascade shows that on average 18% of the total diabetic population was then lost to 
follow-up at the stage of being told about their diagnosis by a healthcare provider, with a 
range of 0% to 26% (Figure 14). 
 
Third, among those who reported completing the first two steps in the cascade, figure 14 
shows that an additional 16% of the total diabetic population was lost to care and follow 
up at the stage of receiving advice on lifestyle modification, with a range of 5% to 15%.   
 
Fourth, a further 2% was lost to care between the stages of receiving advice and receiving 
any medication treatment (range 3% to 10%), including oral medication or insulin, for 
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diabetes control. Overall the analysis of the data from the 10 surveys shows that the 
percentage of the diabetic population who completed the care cascade in different 
countries averaged 24% with a range of from 9% to 58%. (Figure 14) 
 
The pattern of care cascade by country varied. In Benin, there was a very rapid drop in 
the first step with 60% of patients with diabetes not having their glucose measured. 
Thereafter, there was a steady decline with a 14-percentage point decline from patients 
who were aware of diagnosis to receiving advice. Overall, just 22% of the patients with 
diabetes received medicines (Figure 15a).  
 
Figure 15a 
 
In Comoros, which had the second best profile of care cascade, there was steady decline 
at each step with 33% of patients received advice and medication overall. (Figure 15b)  
 
Figure 15b 
 
In Guinea, which has a weak health system and has been affected by the Ebola virus 
outbreak, there was a sharp drop at the first step as with Benin, with 40% of patients 
with diabetes having glucose measured. A steady decline after each step therafter meant 
that overall just 20% of patients received advice and 17% received medication. (Figure 
15c) 
 
Figure 15c 
 
The pattern of cascade in Liberia, which also has a weak health system and has been 
affected by the Ebola virus outbreak, mirrored that in Guinea, but decline at the first step 
was wach greater. Only 19% of patients with diabetes had their glucose measured and 
overall the proportion of patients receiving advice and medication was 8%. (Figure 15d) 
 
Figure 15d 
 
In Mozambique, the patttern was similar to that observed in Benin and Guinea, with a 
sharp drop at the first step in the care cascade by 69% so that only 31% of diabetic 
patients had their blood glucose measured and a steady attirition in the care cascade 
meant that 19% of patients received medication. (Figure 15e) 
Figure 15e 
 
Namibia had the best profile of diabetes care cascade among the 10 countries studied, 
with a less sharper decline of 39% at the first step, with 61% of patients with diabetes 
having their glucose measured. The declines at each step thereafter were less marked 
such that 39% of patients with diabetes received advice and 36% received medication. 
(Figure 15f) 
 
Figure 15f 
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The cascade pattern in Seychelles was different to the rest of the study countries. 
Seychelles, which has one of the highest prevalence rates of diabetes in SSA (see Section 
1 of the report), had by far the biggest proportion of diabetic patients (92%) whose blood 
glucose levels were measured. However, there was a sharp decline at step two with a fall 
of 52 percentage points, so that just 40% of patients were aware of their diagnosis and 
24% were receiving medication. The findings suggest a well functioning screening 
programme but a weak health system where there is considerable loss to follow up of 
patients diagnosed with diabetes. (Figure 15g) 
 
Figure 15g 
 
In South Africa, the pattern of cascade of care mirrored that of Namibia, but the lost to 
follow-up at each step was greater than that observed in Namibia, so that 29% of patients 
were able to receive advice and 26% receive medication. (Figure 15h) 
 
Figure 15h 
 
Tanzania had the third best profile after Namibia and Comoros. Following a decline of 
50% in the patients at the first step, one half of patients had their glucose measured, and 
almost all of those receiving a glucose test were aware of their diagnosis (49%). Steady 
attrition at steps 3 and 4 meant that 34% of patients with diabetes received advice and 
29% received medication. (Figure 15i)    
 
Figure 15i 
 
Togo had the least favourable profile, along with Guinea and Liberia, with a sharp drop 
at the first step, with 29% of patients receiving a test to measure their glucose levels. 
There was a decline at each step so that just 9% of patients received advice and only 7% 
received medicines. (Figure 15j) 
 
Figure 15j 
 
The analysis of diabetes care cascade in 10 countries clearly shows the health system 
challenges faced by countries of SSA in managing diabetes, with unmet need at every 
step of the care process that leaves the largest proportion of patients with diabetes going 
undiagnosed. For those diagnosed with diabetes the health systems are not able to 
provide the service needed, with the majority of the patients with diabetes not receiving 
advice and the medication they need. Unmet need and suboptimal care means that 
patients will likely have delayed presentation to the health system and receive advice and 
medication late in the care process, with adverse effect on health outcomes. Not only do 
unfavourable health outcomes produce difficulties for patients and their families due to 
ill health, they also have adverse economic consequences for patients, their families and 
the economy at large.  
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We present in the next section our estimates on the economic consequences of diabetes 
in SSA. 
 
 
 
Economic consequences of diabetes in sub-Saharan Africa 
 
Beyond ill health and lowering quality of life substantially, diabetes mellitus imposes a 
non-negligible financial burden on affected individuals, families and societies. While 
patients with diabetes face increased direct costs of illness through medical treatment of 
the disease, its comorbidities and sequelae, they also simultaneously experience income 
losses through reduced productivity and disability, which in severe cases leads to 
inability to work.  
 
Economic burden of diabetes to individual patients 
 
Earlier studies in SSA have found that in the early 2000’s treatment costs of diabetes for 
oral medication and insulin for one course (30 days) amounted to wages earned between 
1.1 and 8.4 days.222 These costs did not take into account complications and sequelae or 
additional medical needed.223 Other studies have estimated direct cost of diabetes per 
person per year at $138 in Tanzania in 1989/1990223, and $489 in Cameroon in 2001224. 
International Diabetes Federation estimates put per person per year expenditures in 
2015 in SSA for diabetes at $243-$419.225 
 
Given the paucity of data on cost of diabetes in SSA, we undertook a cost of illness study, 
published elsewhere, to ascertain direct costs of diabetes. We estimated that in 2015, in 
SSA, overall health expenditure including average direct costs of diabetes and its 
complications was $264 per person with diabetes, including both those diagnosed and 
undiagnosed.226 These estimates relied on a set of assumptions using data from 
developed countries and are likely to underestimate the costs of diabetic comorbidities 
and sequelae, given the larger proportion of undiagnosed and untreated cases in low 
income countries227 who are more likely to experience potentially costly 
complications.228,229 Hence, notwithstanding these limitations we argue that the overall 
number provides a lower bound of direct treatment costs in developing countries. A 
summary of the methodology and assumptions is provided in supplementary appendix 
and a more detailed discussion of the methods and the results is available in Bommer et 
al.227  
 
In SSA out-of-pocket expenditures are estimated to be 50% of overall health 
expenditures.230 This proportion is likely to be substantially higher for diabetes, and will 
often be prohibitive, producing financial barriers to access and leading to many diabetic 
individuals not seeking care (and thus avoiding short-term treatment costs but 
potentially accumulating larger health deficits which lead to even higher long-term direct 
costs through more severe sequelae and in addition to shorter life spans). Co-morbidities 
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and target organ damage for diabetes will result in many instances in ‘catastrophic’ or 
‘impoverishing’ healthcare expenditures, shifting many patients and their families 
beneath the poverty line.231 Simultaneously, these adverse effects are likely to be 
perpetuated in absence of adequate social security systems, where families may attempt 
to offset such catastrophic expenditures by shifting children into workforce, thus 
effectively bereaving them of any future prospects of financial wellbeing. 
 
Indirect costs of illness on individual level result from productivity losses of diabetic 
workers during their productive years (as costs of early mortality are not borne by 
diseased individuals themselves we do not consider this position in this section). These 
losses can result from absenteeism (sick workers failing to appear for work), 
presenteeism (unfit workers coming into work where they are unable to perform to full 
capacity), and employment effects (the decision to drop out of labour force temporarily 
or permanently).227 
 
Panel 2: Labour-market effects of diabetes 
A meta-analysis of labour-market effects of diabetes estimates that the drop in labour 
force participation of diabetic individuals can range between 10.5 to 17.8% for women 
and 8.9 to 17.8% for men. 227 Male diabetics who are in labour force are found to be 
absent from work for 1.7 to 14.2 additional days due to diabetes, whereas absenteeism 
due to diabetes for women is estimated at 1.5 to 2.9 days. Finally, diabetic workers’ 
productivity losses while at work (presenteeism) are found to vary between 4.5 to 5.5% 
for men and 2.0 to 3.0% for women relative to non-diabetics. The underlying empirical 
evidence largely draws on data from high-income and upper-middle income countries. 
Effects on labour market participation are based on studies from the 
USA232,233,234,235,236,237, Australia238,239, Canada240, Taiwan241 and Mexico242, and 
absenteeism studies from USA236,243 ,244, and Slovenia245,, and presenteeism estimates are 
based on studies from the US235,237 and Canada246. 
 
It is hence not known whether these labour market effects accurately capture the 
situation in SSA. For instance, the lack of job security and the importance of informal 
work on SSA labor markets may translate in a lower propensity of individuals to be 
absent from work, thus leading to increased presenteeism. Moreover, the combination of 
limited capabilities for blood sugar levels management and a shortage of preventive 
treatment is likely to lead to higher rates of severe complications in the long-run, hence 
increasing the rate of labour force drop-out. 
  
Furthermore, while in high-income-country productivity losses may be partially or fully 
offset by social security systems (e.g. continued pay during sick leave, insurance 
payments in case of permanent disability), in SSA they are likely to fully accrue at the 
level of sick individuals through foregone wages from formal or informal work as well as 
reduced agricultural yield in the case of subsistence farmers.  
 
Economic burden of diabetes to countries 
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In addition to adverse effects to individual wellbeing and socioeconomic conditions, the 
increasing prevalence of diabetes is creating a considerable economic burden to health 
systems worldwide. The economic burden of diabetes in SSA is also thought to be large, 
though no recent estimates are available. 
 
A recent study by Bommer et al., analysed direct health expenditure and indirect costs of 
diabetes caused by premature mortality and disability, to estimate the global economic 
burden in 2015 to be 1.7% of world GDP. 227   
 
Based on the same approach and using prevalence, mortality and direct health 
expenditure estimates from the 7th edition of the IDF Diabetes Atlas247  for 45 SSA 
economies, as well as national account data from the World Development Indicators 
database248, we estimated the overall costs of diabetes in 2015 for SSA to be $16.49 
billion or 0.80% of cumulative GDP of the whole of SSA.  
 
Around $11.04 billion of the $16.49 billion (66.97%) was in Southern Africa, mainly 
driven by the relatively wealthy South Africa, which contributes the largest share to the 
overall economic burden is SSA, and $2.57 billion (15.58%) in Eastern Africa (Figure 16). 
Around 76% of this burden ($11.54 billion) arose from indirect costs (Figure 16).   
 
Figure 16 
 
Direct costs were estimated based on countries’ per capita health expenditure assuming 
a fixed ratio between the age- and sex-specific treatment costs treatment costs for 
diabetic and non-diabetic individuals.246,249 Indirect costs were defined as productivity 
losses due to mortality or disability, as measured by forgone labour earnings. As the 
wage data from SSA countries are scarce, labour earnings were proxied by the labour 
income share in GDP per working age person as measured in 2015 US$. A more detailed 
discussion of the methodology, including necessary data imputations, is provided in 
Bommer et al. 227  
 
Productivity losses consisted of four components: (i) premature mortality (which 
amounted for 74.68% of total indirect costs), as dead individuals are permanently 
unavailable to the labour market (ii) diabetes-related complications and malaise, which 
make diabetic patients less likely to participate in the work force (“drop out” accounting 
for 16.60% of total indirect costs (iii) more likely to take sick leave (“absenteeism”, 
accounting for 2.77%) and (iv) decrease their productivity while working 
(“presenteeism”, which amounted to 6.13%) (Figure 17). 
 
Figure 17 
 
An important question for health systems and governments in SSA is how the economic 
costs of diabetes are going to evolve in the short- and medium-term.  
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To investigate this important question, we used five-yearly United Nations Population 
Prospects data for the years 2015 – 2030 (using the medium variant provided by the UN 
Population Division as well as projected urbanization rates projected by the UN250,251 
when estimating our projections of economic cost. Our projected economic costs also 
take into consideration real GDP and GDP per capita growth, the projected change in the 
demographic composition, future population size as well as urbanization (as an urban 
sedentary lifestyle is considered an important risk factor for diabetes).252 The main 
scenario we present further assumes that age- and sex-specific mortality and diabetes 
prevalence would grow at a rate of 5% per year, as increases in wealth may further 
amplify the adoption of Western consumption patterns.  
 
Our estimates suggest that the economic costs are projected to increase from $16.49 
billion in 2015 to $52.35 billion (in 2015 prices) (Figure 18). Using an alternative 
scenario, which is more optimistic and assumes that future changes in lifestyle are 
already accounted for by urbanization, suggests that the economic costs will increase 
from $16.49 billion in 2015 to $25.44 billion in 2030 (using the medium variant 
provided by the UN) (Figure 18). The presented 95% confidence intervals (blue and 
green dashed lines) reflect uncertainties in prevalence and mortality estimates as well as 
labour market effects.  
 
Based on the main scenario projections, the economic burden in 2030 is forecasted to 
reach 4.60% of GDP in Southern Africa, 1.34% in Eastern Africa, 0.87% in Middle Africa 
and 0.25% in Western Africa (Figure 19).  
 
Figure 19 
 
The high economic burden SSA is predicated to face and the high indirect costs create a 
strong incentive for policy makers to increase efforts to reduce diabetes-related 
complications and premature mortality. But, as the analysis of this report shows health 
systems in sub-Saharan countries are not prepared to effectively manage diabetes, the 
current health systems response is weak, the care provided suboptimal and the unmet 
need very large.  
 
If diabetes is effectively managed, the health and economic burden it brings could be 
substantially reduced. We explore in the next section the benefits that might be realised 
if diabetes in SSA were to be managed according to international guidelines and 
evidence. 
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Benefits of scaling up diabetes interventions in sub-Saharan 
Africa 
 
Effective treatment of diabetes in rapidly developing countries is likely to require 
complex considerations on expansion of services for early diagnosis and for those 
diagnosed how to dispense the best available treatments to the maximum number of 
patients who could benefit from therapy, all within tight cost constraints.  
 
Among people with diabetes, high blood pressure, disordered lipid profiles and poor 
glycaemic control constitute the three principal co-existing risk factors for morbidity and 
mortality, and the aim of diabetes treatment is to prevent their long-term complications.  
 
Comparing Benefit-Based Treatment with Treat to Target Strategies in an 
African context 
 
In SSA patients with diabetes experience unmet need at every step of the care process, 
with the result that the majority of patients are undiagnosed, and a large proportion of 
those diagnosed receive sub optimal treatment and care. In addition to the adverse 
health consequences, diabetes leads to economic burden for individuals, families and the 
economy. Prevention, early diagnosis and effective treatment of diabetes could help to 
alleviate the burden on health and the economy. 
 
In treating diabetes, while all three risk factors impact on both large- and small-vessel 
complications, there are substantial differences in their relative impact, in the 
complexity of their treatment and monitoring regimens, in their therapeutic window, 
and in the costs of therapy. There are important interactions between the risk factors for 
both the large vessel (coronary heart disease, stroke) and small vessel (retinal, renal, 
neuropathic) complications of diabetes,253,254,255 with treatment guidelines emphasizing 
the importance of addressing all three256.  
 
For both blood pressure and lipid therapies, there has been a move towards targeting 
treatment to individuals at higher levels of risk, rather than according to levels of blood 
pressure or lipids257,258,259, under the understanding that different individuals may 
experience different benefits and risks from therapy depending on their co-morbid 
conditions. For example, people with previous myocardial infarction or stroke may 
benefit from being initiated on treatment at lower levels of blood pressure or LDL-
cholesterol than others. T in both high income and middle income settings, the risk-
based approach to treating blood pressure, termed benefit-based, tailored treatment 
(BTT), has been shown to be more effective and less costly, than treating blood pressure 
to target levels (a treat-to-target (TTT) strategy).257,260,261  
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The question remains whether a BTT approach or a TTT approach would overall be 
beneficial to people with diabetes in SSA for overall diabetes risk factor management.  
 
We constructed a microsimulation model to compare the approaches to reducing the risk 
of major macrovascular (myocardial infarction, stroke) and microvascular (neuropathy, 
retinopathy, and end-stage renal disease) complications of diabetes among two 
populations aged 30-70 years old in SSA, from Malawi (N=35,730), “participating in the 
Karonga Prevention Study262 and from Ghanaian plus South African datasets (N=3,938 
and 2,352 respectively),263 representing the spectrum for SSA.    
 
Two alternative management approaches were compared. The first was a “treat to target” 
(TTT) strategy involving titration of blood pressure treatment agents, statins and glucose 
lowering drugs to predefined targets. The second was a “benefit-based tailored” (BTT) 
treatment strategy, which comprised treating individuals at high macro-vascular risk 
with blood pressure treatment agents and statins, and those at high micro-vascular risk 
with glucose lowering agents, until they achieved low risk levels. Thus treat to target 
involved treating individuals with blood pressure treatment agents until they achieved a 
blood pressure <130/80 mmHg256; with a statin to a low-density lipoprotein <2.59 
mmol/L (100 mg/dL)264; and with metformin, sulfonylureas and, if needed, substituting 
the sulfonylurea with insulin, until they achieve a hemoglobin A1c <7%265.  
 
The benefit tailored treatment strategy involved treating individuals with a 10-
year combined risk of myocardial infarction (MI) and stroke >10% with antihypertensive 
agents and a statin until their risk lowered below the 10% threshold (provided blood 
pressure remained >110/55 mmHg for safety), and for those with a lifetime risk of the 
three major micro-vascular outcomes (blindness, end-stage renal disease, and 
amputation secondary to neuropathic ulcer) of >4%, treating elevated glucose with 
metformin, sulfonylureas and, if needed, substituting the sulfonylurea with insulin until 
lifetime micro-vascular risk was below 4% (provided fasting blood glucose remained 
>3.33 mmol/L [60 mg/dL], for safety).  
 
We employed WHO guidelines for blood pressure medication and statin medication 
choice,256 and the Yale Diabetes Center Guidelines for dose escalation algorithms for 
metformin, sulfonylurea and insulin.266 Cases averted, disability-adjusted life-years 
saved (based on disability weight values estimated by the Global Burden of Disease 
Project),267 and drug costs for therapy (based on per-unit global buyer cost estimates 
from the International Drug Price Indicator Guide)268 were integrated over the simulated 
life-course of all persons with diabetes who were alive, or born, during the next 10 years, 
per standard cost-effectiveness guidelines269. DALYs and costs were discounted at a 3% 
annual rate, and costs were expressed in 2016 U.S. Dollars. 
 
We found that a BTT strategy was more effective, and cost-effective, than a TTT strategy 
from a population perspective (Table 8). Although a similar fraction of people with 
diabetes were typically recommended treatment of any kind (a mean of 86% under TTT 
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versus 88% under BTT in Malawi; see Table 8), those typically treated with the BTT 
strategy were treated more intensively (4.5 versus 3.5 medications per person, 
respectively).  
 
As shown in Table 8, the BTT strategy would recommend more adults with diabetes to 
receive blood pressure lowering agents to a significant extent, and increase to a non-
significant extent the number treated with statins and glucose lowering agents, as 
compared to TTT. Correspondingly, the BTT strategy was estimated to avert two to four 
times as many macro-vascular events (MIs and strokes), but did not significantly differ 
from the TTT strategy in the number of micro-vascular events prevented.  
 
Using the TTT strategy the estimated total drug costs in 2016 would be $1,346.6 million 
(CI: 471.1- 2,206.7 million). With the BTT strategy, the total drug costs would be higher 
at  $1,407.9 million (CI: 464.7 - 2,332.5 million). In terms of total DALYs averted, the 
benefits of BTT were higher, however (Table 8) with BTT leading to saving of 1.9 million 
DALYs (CI: 0.9 – 3.4 million) and TTT 1.2 million DALYs (CI: 1,161.3 (0.6 - 2.1 million). 
 
With BTT, the average costs were between $137.5 and $2,600.2 per DALY averted (Mean 
$743.4) versus $227.6 to $4,047.5 per DALY averted (Mean $1,159.5) for the TTT 
strategy (Table 8).  
 
The results show substantial benefits of effective scale up of diabetes services to address 
unmet need. The question remains on the ability of countries to strengthen health 
systems to respond to the needs. There are encouraging examples of successful models of 
diabetes care emerging in low-income countries and in SSA. In the next section we 
explore these models and provide country case examples of innovative approaches 
introduced in the SSA context for effectively managing diabetes to illustrate what might 
be possible in the future.  
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New and established service delivery models for managing 
diabetes mellitus in sub-Saharan Africa 
 
The environmental and genetic determinants of diabetes and its care exhibit great 
variation in SSA. Yet, diabetes has been studied in much less detail in SSA countries than 
other parts of the world. Most studies on diabetes originate from Western countries 
where international guidelines for management of diabetes typically originate. Few 
studies exist on innovative and country responses that have helped to manage diabetes 
mellitus, and the barriers to its effective management.  
 
We undertook a systematic review to examine current approaches to diabetes care in 
SSA (See supplementary appendix for methods and study design). In addition, we 
reviewed briefly current practices in eight countries (Botswana, Ethiopia, Kenya, Malawi, 
Mali, Rwanda, Senegal and South Africa) and undertook detailed country studies in 
Ghana and Tanzania, using a proprietary tool (SYSRA)270, which has been used 
previously for tuberculosis271, HIV272,273, malaria274, mental illness275 programmes in a 
number of settings, including several African countries276, and was adapted for diabetes 
to enable rapid and simultaneous assessment of the health system and the diabetes 
program. We also assessed new technologies that are currently in use for health and 
could be used to improve diabetes care. We describe below our findings: first the results 
of the review, second the brief case studies, third the detailed cases on Ghana and 
Tanzania, and fourth technological innovations.  
 
The review identified 467 studies, of which 32 from 11 different countries (Cameroon, 
Eritrea, Ethiopia, Ghana, Kenya, Malawi, Mozambique, South Africa, Sudan, Tanzania 
and Uganda) met inclusion criteria (Supplementary appendix).  
 
In many countries of SSA diabetes care is still largely available only in hospital setting, 
requiring patients to travel great distances to access services and follow-up care which is 
important for effective diabetes management. As a result several countries in SSA have 
introduced new care delivery models for managing diabetes care at primary health care, 
community or home setting. 
 
Cameroon and Tanzania, have attempted to introduce community-based management of 
diabetes.277 In Ethiopia, physicians and diabetes-trained nurses have travelled from 
hospitals to peripheral medical centers for training and care provision with early 
encouraging results in improving access to services.278,279 In Cameroon, facility-based 
interventions for high blood pressure and diabetes with task shifting and nurse-led care 
in rural health districts significantly improved retention levels for management of 
patients.280 Similarly, in Kenya, it was possible to devolve management of high blood 
pressure ad diabetes to rural primary health care clinics with good retention rates and 
control.281  
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In South Africa, a chronic disease outreach programme in the public sector, which used 
primary health care nurses to provide educational and follow up advice to patients with 
diabetes, improved early detection and referral of high risk, poorly controlled patients to 
specialist centres.282 Decentralisation of diabetes management to community level was 
also successful in the private sector in South Africa with a community-based capitation 
and risk-sharing model for diabetes management, where the care of diabetes was 
transferred to primary care physicians working in community-based facilities affiliated 
with a diabetes and endocrinology centre. The scheme led to major reductions in hospital 
admission rates for both acute metabolic emergencies and all causes, reduced costs, 
delayed progression of micro-vascular complications, and improved outcomes.283 Nurse-
led diabetes care, with nurse-led protocol and education-based system, was also shown 
to be successful in rural Kwazulu Natal in South Africa with improved control of HbA1c 
levels, and higher satisfaction for patients, their families and health workers284, but the 
improvements in glycaemic control achieved at 18 months following the introduction of 
the scheme were not sustained at 48 months, although the HbA1c levels at 48 months 
were lower than baseline figures285. As with South Africa, introduction of protocol-driven 
nurse-led management of diabetes in primary care setting in rural and urban Cameroon 
also led to improvements in glycaemic control and blood pressure.286 
 
Community health worker (CHW) model of outpatient care was introduced in one study 
in South Africa for diabetes and hypertension that involved monthly home visits, 
counseling services, and access to monthly supplies of medication. While the CHW 
model improved hypertension control, the same was not true for diabetes care however, 
with 26% of the patients at the clinic showing improved diabetic care in comparison to 
9% of the CHW-targeted home visit patients.287 In Cameroon, integration of care for high 
blood pressure and type 2 diabetes was effectively achieved in eight rural health districts 
by task shifting to non-physician clinician facilities, with improved control in patients 
attending services.288 In Cameroon, a pilot study which trained traditional healers in 
health promotion for diabetes and referral for glucose testing showed effective 
collaboration of traditional healers with the diabetes programme to improve referral 
rates.289  
 
Home glucose monitoring has also been introduced in SSA. For example, in South Africa 
home glucose monitoring using urine testing has been introduced even to illiterate 
patients with good compliance and lower random glucose levels compared to non-
compliers.290 In Kenya, a home glucose-monitoring programme that used mobile phones 
to enable CHWs to regularly communicate to patients to modify the dose of insulin 
injections helped to improve HbA1c levels.291  
 
Patient education has also been used in several settings to improve services across the 
care continuum and to decentralise care away from hospitals to patient level. For 
example, in Cameroon, motivational counseling and education was integrated into a 
screening program to improve rates of follow-up for newly diagnosed individuals.292 In 
South Africa group education was used at community health centers to improve patient’s 
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knowledge and management of diabetes, but there was no improvement in diabetes self-
care activities, weight loss, HbA1c levels and quality of life, or improvements in self-
efficacy, locus of control, mean blood pressure, mean weight loss, mean waist 
circumference, and mean total cholesterol levels.293 Another study from South Africa 
showed that group education programme for patients with Type 2 Diabetes could be 
implemented in rural areas with a dietician or health promoter to provide a supportive 
environment for patients for learning and coping with significant improvement in 
adherence to a diabetic diet, physical activity, foot care and the perceived ability to teach 
others, but no significant change in smoking or adherence to medication.294 In Tanzania, 
a hospital-based education programme for children with Type 1 Diabetes on symptom 
management, correct insulin storage and insulin administration led to reduction in 
severe hypoglycaemia, but no improvement in HbA1c levels.295 In Mozambique, twinning 
programmes have been used to successfully establish patient education programmes and 
to improve their effectiveness.296 
 
In addition to patient education, health-provider education at hospital, primary health 
care and community-level has been used to improve early recognition of diabetes and 
diabetic sequelae, and to enhance disease management in SSA. In Tanzania, where 70% 
of leg amputations occur in diabetic patients, training of healthcare personnel at 
different levels and centres in diabetic foot management has led to improved case 
finding, earlier referrals, establishment of well-functioning foot clinics, and strengthened 
management of diabetic foot ulcers with better health outcomes.297 In Eritrea, a co-
operative diabetes project, which emphasised multidisciplinary training of physicians, 
laboratory scientists, diabetes nurse practitioners, patient educators, and dieticians and 
improved quality of laboratory services, led to improved management of diabetes with 
better HbA1c levels.298 Multidisciplinary training for diabetes, involving physicians, 
dietitians and nurse educators and pharmacists has also been introduced in Ghana to 
strengthen diabetes services299, while raining of patient educators has been introduced in 
Sudan300. 
 
Development of new models of diabetes care and attempts to transition in some 
countries of SSA to primary care, community- and home-based management of diabetes 
has been facilitated by the availability of electronic medical records (sometimes building 
on existing systems for HIV)301, and the use of treatment protocols and guidelines, which 
have helped to improve the consistency and quality of diabetes care302.  
 
Some countries such as Malawi have successfully used existing service delivery platforms 
and expertise for management of tuberculosis, which is associated with diabetes and has 
well-established care models, based on directly observed therapy, as well as structured 
monitoring and reporting mechanisms.303 Others, such as South Africa, have successfully 
used mobile units for HIV counselling and testing as an entry point for screening for 
NCDs (high blood pressure and diabetes) with high yield of new case, but linkage to care 
and follow up was noted to be a challenge.304 Similarly, in Uganda, community-based 
HIV testing campaigns were used to offer offering diagnostic, preventive, treatment and 
referral services for HIV, malaria, TB, hypertension and diabetes, with the identification 
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of high burden of HIV, high blood pressure and diabetes with effective linkage to care.305 
In Kenya, HIV counsellors were trained to screen for diabetes and high blood pressure in 
home-based screening and local district hospital based staff conducting community-
based screening, with effective uptake and results for both approaches, but in both 
groups there was low levels of follow-up with only around one fifth of patients returning 
after a random glucose test. 306 
 
African experience of diabetes management suggests a particular distinctiveness with 
strong reliance on non-physician health workforce including nurses, community health 
workers, and health extension workers, as well as traditional healers in some settings. 
Several countries, such as Botswana, Ghana, Ethiopia, Kenya, Malawi, Mali, Rwanda, 
Tanzania and South Africa included in the study, have introduced innovative approaches 
to address resource constraints when managing diabetes (Panels 3- 10).  
 
Panel 2: Botswana country case study 
Botswana, a country of 2.2 million people, which has introduced a highly successful 
response to the HIV epidemic in SSA, provides diabetes care largely through the public 
sector (see supplementary appendix – Botswana case). In 2015, the prevalence of 
diabetes was estimated to be 4.0% in adults aged 20-79 years.307 Specialist human 
resources for diabetes are few in the country, with one adult endocrinologist (in the 
private sector), two paediatric endocrinologists (in the public sector), and two nurses 
with full training in diabetes education and care (one each in private and public sectors).  
 
In Botswana, patients with diabetes have access to general nursing, psychology, and 
social work services both in the private and public sector. In addition, among the 
community health care workers six diabetes youth leaders, who are fully trained in 
diabetes peer education, provide diabetes education and public health screening 
campaigns, and are involved in running diabetes youth camps.  
 
Insulin treatment and oral hypoglycaemic drugs metformin and glibenclamide are 
available to all citizens free of charge. Patients can receive diabetes care in local clinic or 
a healthcare facility that are typically available within 5 km of households, and can have 
blood and urine tests for diabetes (free of charge), which are analysed in a local 
laboratory in the tertiary centres (with capacity to test for HbA1c, urea and electrolytes, 
blood glucose, full blood count, blood gas, thyroid function, insulin concentration, and 
C-peptide. Tests such as urine microalbumin, coeliac screen, insulin autoantibodies, 
intracytoplasmic autoantibody, and glutamic acid decarboxylase antibody are outsourced 
to South Africa). In addition, clinics and health facilities provide blood glucose test strips 
to all patients with diabetes free of charge.  
 
Diabetic patients with complex co-morbidities and children with diabetes are managed 
by specialists in the tertiary facilities located in major urban centres—for example, the 
Paediatric Endocrinology Clinic in Princess Marina Referral Hospital in Gaborone. 
Similarly, yearly ophthalmology examinations with specialised cameras are available in 
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tertiary centres. The Diabetes Association of Botswana has 100 members and is involved 
in diabetes education, care and support.308  
Panel 3: Ghana country case study 
Ghana has a population of approximately 26.3 million people.309 The prevalence of 
diabetes in 2015 was estimated to be 1.9% in the adult population aged 20-79 years310, 
but an estimated 70% of diabetics in Ghana are currently unaware of their condition.311 
The National Health Insurance Scheme (NHIS) covers 38% of the population and covers 
maternal and child-health services as well as curative services, but not preventative 
services or medical equipment, including for NCDs or diabetes such as prosthetic 
limbs.312  
 
The national NCD Control Programme, which was established in 1992, coordinates inter-
sectoral response in partnership with other agencies in the health sector for NCDs and 
diabetes to promote lifestyle changes and early disease detection.313 Curative facilities for 
diabetes treatment are available in urban areas, but despite the planned expansion of 
diabetes services in the 2014 Non-Communicable Disease Strategic Plan, the majority of 
the urban population and the rural populations remain without access to diabetes 
diagnostic or follow-up care.  
 
The lack of clinic access, screening equipment, and health workers who understand how 
to diagnose and treat diabetes remain particularly apparent in rural areas where 
infrastructure is weak.314 While selected medical treatments, including two-monthly 
insulin refills, are paid for by the NHIS for those covered by the scheme, patients still 
face difficulties in following treatment guidelines and accessing pharmacies, but face 
financial barriers as in hospitals ad health centres they are of ten charged for tests and 
examination, as well as for prosthetic limbs. Patients without NHIS coverage face 
encounter further financial barriers to treatment.315 
 
Panel 4: Ethiopia country case study 
Ethiopia, the second most populous country in SSA with a population of around 97.0 
million people, has experienced strong economic growth in 2005-2014 of average 10% 
rise in GDP each year, with rapid urbanisation and nutritional transition to energy rich 
foods and beverages.316  
 
Ethiopia has effectively used this economic growth and overseas development assistance 
for health to increase per person health expenditure from $16.1 in 2007/08 to $25.0 in 
2013. The Five Year Health Sector Transformation Plan 2015-2020 has set the goal of 
expanding community-based health insurance from 1% in 2015 to 50% in 2020.317 The 
prevalence of diabetes in Ethiopia was estimated by International Diabetes Federation to 
be 2.9% in the adults aged 20-79 years, with an estimated 1.33 million deaths.318  
 
Diabetes services are delivered mainly at primary health care centres. Specialised clinics 
located in the major university teaching hospitals also provide diabetes care either by 
endocrinologists or by general internists who have received short-term training in 
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diabetes management. One teaching hospital in Addis Ababa employs the only five 
endocrinologists in the country. Nurses, health officers and general practitioners provide 
most of the diabetes care in health centres and general hospitals. There are plans to 
extend the role of urban health extension workers to provide prevention and education 
services for diabetes. In 2014 with an estimated six out of 10 health facilities, excluding 
health posts.319 However, the majority of patients with diabetes are undiagnosed. A 
cross-sectional population-based survey in northwest Ethiopia, which estimated the 
prevalence of diabetes mellitus among adults aged 35 years and older to be 5·1% for 
urban dwellers and 2·1% for rural dwellers, showed that 69% of the cases diagnosed with 
diabetes during the survey had not been previously diagnosed.320 The Ethiopian Diabetes 
Association which has more than 20 000 members undertakes advocacy activities, 
andeducation for healthcare professionals and for people with diabetes. 
 
Panel 5: Kenya country case study 
In Kenya, the prevalence of diabetes was estimated to be 3.6% in the adult population 
aged 20-79 years, with almost 60% of cases undiagnosed.321 Diabetes services at 
community and primary care levels are hampered by inconsistent availability of drugs, 
equipment and testing for HbA1c. Consequently, patients are often referred to 
hospitals.322 High costs and out-of pocket expenditures impede access to drugs for 
diabetes.323  
 
Following the launch of the national diabetes strategy in 2010 Kenya began to expand 
health system capacity for managing diabetes, with training of healthcare professionals 
and community health workers, developing national guidelines, and expanding diabetes 
screening.324 In particular there is an emphasis in increasing the number of community 
health workers and training them in the management of diabetes to enhance access to 
diabetes services.325 
 
Panel 6: Malawi country case study 
Malawi, which has a population of 16 million, is one of the poorest countries in SSA, and 
around a 65% of the Malawian population lives below the poverty threshold of less than 
US$1 a day. The prevalence of diabetes in Malawi was estimated by the International 
Diabetes Federation to be 2.7% in the adult population aged 20-79 years in 2015.326 
However, an earlier study, which used the STEPS survey data from 2009, estimated the 
prevalence of diabetes (prevalence of raised fasting blood glucose or currently on 
medication for diabetes) to be 5.6%.327 One study of clinic attenders in the country’s 
teaching hospital showed that 75% of the patients had poorly HbA1c levels >7.5%, 50% 
had systolic blood pressure >140mmHg, 34.7% had nephropathy, 34.7% had 
retinopathy, and 46.4% had neuropathy.328 Other studies have shown care to sub-
optimal due to resource constraints.329  
 
Malawi has low levels of health human resources with two doctors and 38 nurses per 100 
000 population. There is one endocrinologist in the country. However, in spite of the 
resource constraints, Malawi has introduced successful programmes for HIV, 
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tuberculosis and malaria to reach the MDG 4 target of halving child mortality. It has also 
incorporated management of high blood pressure and diabetes in its essential health 
package with evidence-based national guidelines and standards of care that is being 
introduced in primary health care centres with services provided predominantly by 
nurses.  
 
Malawi is piloting the WHO package of essential noncommunicable disease 
interventions for primary health care in low-resource settings and has started a 
programme to train 1000 health workers by 2016. However, low numbers of health 
workforce and other resource shortages mean that patients with diabetes are under 
diagnosed and when diagnosed not well controlled with high levels of complications.330 
To overcome resource constraints and to improve consistency of diabetes care provided 
Malawi has introduced new service delivery models by using DOTS approach used in 
tuberculosis care to manage diabetes331, as well as home-based care and peer-support 
successfully used in the management of HIV in Malawi332.  
 
Panel 7: Mali country case study 
Mali is the biggest country in western Africa with a population of 17.3 million, where 
around 45·6% of the population lives below the poverty threshold of US$1·25 per day. 
The prevalence of diabetes in 2015 was estimated to be 1.8% in the adult population aged 
20-79 years.333  
 
In Mali, effective management of diabetes has been hampered by resource constraints: 
there are only two diabetes specialists located in the national hospitals in the capital, 
Bamako; there is a shortage of human resources, medicines and equipment (such as 
blood glucose meters and test strips), leading to delayed diagnosis, suboptimal treatment 
and limited monitoring. To overcome these challenges Mali has introduced a national 
strategy to manage NCDs, with a training programme for diabetes to train 500 health-
care professionals in 2015, establish 30 diabetes consultation sites, improve 
procurement and strengthen supply chain management to increase availability of 
insulin, other anti-diabetic medicines, and equipment, and to prevent stock outs.334 
 
Panel 8: Rwanda country case study 
Rwanda has a population of 10.5 million people335. It has a per capita income of $718.0, 
and 39.1% of population live below the national poverty line336. Rwanda has substantially 
improved social and economic conditions and the health system since the genocide 
against the Tutsi population in 1994, with rapid declines in maternal and child mortality.  
 
In 2004, Government of Rwanda introduced a public health insurance program, 
“Mutuelle de Sante.” Patients covered by insurance pay 10% for healthcare services. The 
ovrnment and development partners meet the cost of the insurance premia and the 10% 
of co-pay for the poorest 25% of the population. More than 90% of the population is 
covered by public or private health insurance.337 The health system is underpinned by 
strong community and primary health care that includes 45,000 community health 
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workers working at village level, 400 health posts and 491 health centres staffed by 
nurses, providing population access to health centres under one hour.338 
 
Estimates from the Rwanda STEPS survey in 2012-13 suggest that around 16.1% of the 
adult population was overweight and 2.7% was obese.339 NCDs are a priority in Rwanda’s 
national development plans, including in Vision 2020, 2013-2018 Economic 
Development Poverty Reduction Strategy, Health Sector Strategy III, Non-
Communicable Disease National Policy, and NCD Strategic Plan.340 Rwanda is 
introducing clinical NCD services and care package across all health facilities, which are 
equipped with, glucose meters, ophthalmoscopes, sphygmomanometers and urine strips, 
and ‘NCD clinic model’ in district hospitals and health centers, but faces a shortage of 
health professionals341. To effectively use existing health staff, Rwanda has introduced 
pre-service and in-service training for management of NCDs, including for diabetes and 
associated risk factors. In order to expand health workforce, Rwanda has created a new 
cadre of health professionals – Home Based Care Practitioners – who are working at 
community level to provide home-based services for diabetes and other NCDs. The NCD 
package has made possible to implement screening and early diagnosis at health clinics, 
annual prevention campaigns and a widespread check-up at the community level. 
 
Rwanda has strengthened its health system to improve diagnosis, care and treatment of 
diabetes and has explicit plans to develop a national, multisectoral diabetes program to 
improve response to diabetes. For example in order to expand access to drugs for 
treating diabetes, oral hypoglycaemic drugs (glibenclamide, metformin) and insulin 
(Insulin regular, Insulin NPH/lente, Insulin mix 70/30) have been added to Rwanda’s 
List of Essential Medicines, which are covered through health insurances and 
systematically available through the NCD clinics located at district hospitals.342  
 
Improved access to diagnostic and treatment services in Rwanda has meant that the 
number of people living with diabetes and requiring close follow-up has increased343,344 
with a commensurate rise in demand for health services. To effectively manage the 
increasing demand and Rwanda has started a programme of task shifting to transition 
chronic disease management to home setting.  The task shifting involves careful 
transitioning of services provided by a degree-holding professional at health facility level 
to a vocationally-trained professional in the community, and has the additional benefit of 
lowering access barriers by reducing the need for travel and long waits at health facilities  
 
Rwanda’s progress in improving diagnosis, treatment and care of diabetes has been 
made possible through joint efforts of public institutions and civil society. In 
collaboration with the ministry of health, the Rwanda Diabetes Association contributes 
to partners’ integrated efforts to assist the public sector with advocacy for diabetes 
inclusion in policy development, strategic planning, and treatment, while also offering 
financial and psychosocial patient assistance.345 As diabetes has been integrated into the 
public health system, local organizations have helped to track the number of patients 
with diabetes in the community.  The number of young people aged 25-years or less with 
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diabetes supported by Rwanda Diabetes Association rose 30-fold in the last 10 years, to 
reach from 33 in 2005 to more than 900 in 20105.346 
 
Panel 9: Tanzania country case study 
Tanzania has a population of 33.9 million, with a growth rate of 3.2% each year, with 
children under 15 constituting 44.1%. Around 46.6% of Tanzania’s population still lives 
in poverty with limited access to water, sanitation and electricity.347 
 
Tanzania has a decentralized health system with three functional levels. District level 
provides primary health care services through dispensaries, health centres and district 
hospitals. Regional Hospitals, with more specialized services, serve as a referral point for 
District Hospitals. Highly specialized care is provided at Referral/Specialized Hospitals. 
There is a mix of public, faith based, private for-profit and private not-for-profit 
providers. 
 
Health expenditure accounts for 7.3% of GDP, and amounts to $49 per person per year. 
Around 33.2% of health expenditures are externally funded through the Health Basket 
Fund, 36.3% from public sources and the rest from private out-of-pocket pay.348  
Tanzania has a National Action Plan for the Prevention and Control of Non-
Communicable Diseases 2013- 2020 as a response to the findings of the 2012 STEPS 
survey, which showed increased prevalence of NCDs, especially diabetes and high blood 
pressure. The Ministry of Health and Social Welfare has established an NCD Unit to 
implement the Action Plan by strengthening leadership and policies for NCDs, building 
capacity, integrating services, and improving monitoring and evaluation.  
 
The National Diabetes Program in Tanzania was established in 2011 as collaboration 
between the Ministry of Health and Social Welfare and the Tanzania Diabetes 
Association – the implementing agency for the Program – in partnership with the 
Association of Private Health Facilities in Tanzania to expand access. The Program in has 
three major goals: (i) o strengthen existing diabetes clinics and establish new ones 
especially at district and regional levels (ii) to train healthcare personnel at all levels of 
care and management of people with diabetes and strengthen referral systems, and (iii) 
carry out community outreach to create awareness on diabetes and encourage lifestyle 
changes.  
 
Tanzania Diabetes Association, which received funding from international NGOs and 
private sector firms, has used existing government facilities and staff (who are salaried 
government employees) to establish 148 diabetes clinics in zonal, regional and district 
hospitals, and provides funding for equipment (e.g. glucometers, sphygmomanometers, 
scales) and training of personnel. No additional staffing or salary bonuses were required 
to establish the clinics. The Program has funded training of more than 2000 healthcare 
staff, including nutritionists, nurses, medical officers, assistant medical officers and 
clinical officers. The network of clinics provides care for around 800,000 people with 
diabetes in Tanzania. Consultations in facilities, laboratory investigations, and diabetes 
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drugs are free of charge to patients at the government pharmacies, but availability of 
medications is tenuous.  
 
In addition to the National Diabetes Program, Tanzania has initiated a National Primary 
Prevention Program as part of the National School Health Program. The project which 
runs from 2014 -2017 seeks to promote healthy eating habits and exercise in schools 
through involvement of students, teachers, parents and food vendors. International 
private firms and the International Diabetes Federation have provided donations to 
support treatment and care of children and adolescents, but beginning in 2017 
Tanzanian government is expected to finance these medications.  
 
All patient visits are provided free of charge to patients and as the government mandates 
that diabetes drugs should be given for free to patients, there are no patient fees collected 
at the district and regional diabetes clinics. All the diabetes medications (with exception 
of the donated insulin and supplies for type I diabetics) are financed and procured by the 
government. While the district and regional hospitals can charge patients up to 75% of 
the cost for most medications, they do not get this revenue for dispensing diabetes drugs, 
and therefore the financial burden of the diabetes medications is partly shouldered at the 
district and regional level. 
 
Panel 10: South Africa Case Study 
In 2014, South Africa had a population of 54 million – compared to 17.4 million in 1960 
– with a total fertility rate of 2.6 and GDP per capita level of $6086.45. Around 65.8% of 
the population lives in urban areas, 64.8% is aged between 15 and 64 years and 28.5% 
aged less than 15-years. Average life expectancy at birth has risen from 57-years in 2009 
to 62.5 years in 2015, following improved treatment of AIDS.  
 
Diabetes is the seventh most common cause of adult mortality.349, The estimated 
national prevalence of type 2 diabetes in people aged 30-years or more is 9%, which 
leads to an estimated 8,000 new cases of blindness and 2,000 new amputations each 
year, and accounting for 78,900 years lived with disability.350 In Cape Town, the 
prevalence in people aged 55-65 years was 22.7% (CI 16.2- 30.2), and 38.2% (CI 21.1-42) 
in the 65-74 year age group.351 There are no reliable data on the prevalence or incidence 
of type 1 diabetes. 
 
The public sector provides care to about 84% of the population and accounts for 4.2% of 
GDP with a yearly per capita expenditure of $140, while the private sector consumes 
4.3% of national GDP for 16.4% of the population with a yearly per capita expenditure of 
$1,400. There are 86.5 specialists per 100,000 beneficiaries in the private sector 
compared to 11.4 in the public sector and a similar shortage exists for general 
practitioners. The majority of the registered 75 endocrinologists are in the private sector.   
 
A network of National Health laboratories provides services to over 80% of the 
population for all standard diabetes related investigations. Not all primary care clinics 
have access to the standard diagnostic equipment, which includes glucometers and 
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strips, urine protein and glucose strips, sphygmomanometers with different cuff sizes, 
scale and tape measure for height and weight, monofilaments to screen for peripheral 
neuropathy, Snellen charts and ophthalmoscopes, and HbA1c test due to budgetary 
constraints.352 Retinopathy screening using retinal cameras is limited to tertiary level 
and at primary level in Cape Town. The essential medicines list includes metformin, 
sulphonylureas (glibenclamide or glimepramide) and human insulins – regular, 30/70 
premix and NPH at all levels of care. Analogue insulins are available at tertiary and 
quaternary hospitals.353 
 
There are two professional diabetes associations: the Society for Endocrinology, 
Metabolism and Diabetes of South Africa354, a scientific society, and the Diabetes 
Educators Society of South Africa, an association of diabetes educators. Diabetes South 
Africa, an NGO, has provided support to and acted as an advocate for all people with 
diabetes in South Africa since 1969. It has a national office and 8 branches around the 
country, which in turn have linkages to over 100 smaller local branches and support. 
 
 
Harnessing new technologies to improve diabetes care in sub-Saharan 
Africa 
 
New technologies for global health have helped to accelerate the fight against infectious 
diseases and maternal and child health. However, technologies currently available for 
diabetes care were developed for use in resource-rich health systems and not for those in 
SSA, which have different and distinctive needs. Consequently, in SSA for diabetes care: 
(i) necessary technologies do not exist – with consequent unmet needs in health systems 
that require the development of novel healthcare technologies (ii) technology exists but 
is not accessible – due to cost and health system factors and (iii) accessible technology is 
not adopted – as a result of factors that hinder the adoption of health technologies that 
are available and accessible.355 
 
The resource-poor health systems in SSA several context-specific challenges: first, there 
is a substantial shortage of health workforce and expertise, leading to inadequate staffing 
for diabetes and healthcare services in general, and impeding the establishment of multi-
disciplinary teams, which play an important role in successful care models for managing 
diabetes in resource-rich health systems. Second, most of the health technologies that 
are necessary to diagnose, monitor and treat diabetes and its complications are not 
affordable to patients and health systems. Third, access to health services is a major 
constraint in SSA, as patients often need to travel large distances to reach health centres 
and when they do access services they cannot afford to pay for healthcare services, 
medicines and diagnostics – as a result experiencing impoverishing 
expenditures.356,357,358,359,360,361  
 
The development of novel low-cost point of care diagnostics offers the potential to 
mitigate some of the constraints in delivering effective diabetes care in these issues that 
has proven particularly promising (Panel 11). 
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Panel 11: Point of care technologies for diabetes care 
New low-cost point-of-care diagnostics services will be critical in diagnosis, 
treatment and monitoring of diabetes in SSA, in particular the distributive model of 
care being developed in several countries that rely on PHC and community-based 
services provided by community health workers, and health extension workers. 
  
Effective early detection of diabetic retinopathy, which may reduce the risk of 
blindness by 95%, currently requires the availability of both clinical staff with 
ophthalmological training and costly equipment to carry out eye exams. Both 
requirements are a major obstacle to care as illustrated by the case of Malawi, a 
country with around 16.4 million inhabitants who are served by just six 
ophthalmologists. New technologies are required to manage diabetes complications 
in such resource-poor settings.  
 
New devices such as the “The Portable Eye Examination Kit (PEEK)” app 
(http://www.peekvision.org) which uses a smartphone and the hand-held “epiCam” 
device (http://www.epipole.com/epicam/) which can capture images digitally for 
store-and forward using a lap-top computer, offer the possibility of screening for 
diabetic retinopathy by health workers in PHC, community-based services and in 
remote rural areas. While these devices still rely on expert analysis and interpretation 
of fundus images, which can be done remotely, distributed screening is possible. In 
future diagnostic algorithms could be used to remotely analyse and provide 
automated grading of such images at considerably low cost.  
 
Peripheral neuropathy, another important complication of diabetes, is where there is 
an urgent need for new diagnostics tools for early detection. The prognosis for 
diabetic peripheral neuropathy is poor if these are not diagnosed early. However, 
accurate diagnosis such diabetic neuropathy represents a major challenge, even in 
the context of resource-rich health systems.362 The development and adoption of new 
non-invasive diagnostic devices that enable point-of-care testing and not require 
specialised training to use, for example SUDOSCAN (http://www.sudoscan.com) and 
NC-stat DPNCheck (http://www.dpncheck.com), could improve screening and early 
detection of diabetic peripheral neuropathy in resource poor settings. 
 
In addition to easy to use diagnostic devices for retinopathy and neuropathy, low cost 
diagnostic devices that enable point-of-care testing of blood glucose, HbA1c, 
glycosuria and proteinuria and could be for screening, diagnosis, treatment initiation, 
and monitoring. If applied with mobile telephones or smart phones these diagnostic 
devices would help to transform prevention, treatment and care of diabetes, which 
could be used for targeted messaging for prevention363, communicating test 
results364, for self-monitoring of diabetes365 (that would help improve adherence and 
reduce the need for follow-up appointments) or to attend clinics when needed366. 
Mobile phones and telephone consultations have been used successfully in resource-
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poor settings for effective management of HIV to improve health outcomes367 and 
could be readily applied for management of diabetes.   
Improving access to existing technologies for better diabetes care in sub-
Saharan Africa 
 
In addition to developing new low-cost technologies for diagnosis and management of 
diabetes, another key challenge is to ensure timely and affordable access to existing cost-
effective technologies. These technologies include appropriate forms of insulin 
commensurate within available budgets368, and medicines, discussed in detail this 
report, as well as miniaturised blood glucose sensors, and strips for testing of urinary 
glucose of protein.  
 
Making the best use of limited resources for expanding access to existing medicines and 
technologies for diabetes care in SSA will require efforts to improve technology 
assessment, procurement and supply chain management to achieve greater value for 
money, better procurement prices and timely delivery of available medicines to avoid 
interruptions to service delivery and treatment.369 
 
Development of ICT infrastructures for health  
The Lancet Commission on Technologies for Global Health355, suggested that strategies 
for strengthening the role of technology in addressing pressing health needs in resource-
poor settings should focus not only on ‘health technologies’ (such as new therapeutics, 
diagnostics, and medical devices), but also on ‘technologies for health’ (that include 
technologies such as communication and transport used in the broader context of health 
systems but impact on health).  
 
Information and communication technology (ICT) has a particularly important role to 
play in improving the management of chronic diseases such as diabetes. While there 
have been efforts to improve uptake of ICT in health systems in SSA, in particular for 
HIV and tuberculosis370, overall, ICT remains underutilised. The current underutilisation 
of ICT may present an opportunity, as the absence of legacy systems would enable 
introduction and adoption of up-to-date ICT platforms and solutions that can utilise 
mobile telephony to enhance access.371,372,373 Integration of electronic health records and 
mobile device data presents an important challenge, however.   
 
While electronic health records were typically not designed to facilitate data sharing, 
mobile data are. New solutions, using ‘cloud technologies’ offer an important 
opportunity for readily capturing and integrating real-time data across multiple mobile 
phones, point of care devices, diagnostics laboratory tests, and electronic health records 
(Panel 12). Such cloud-based systems, which are being tested in SSA for management of 
tuberculosis (Panel 12), would provide a step change in creating a disease monitoring 
system for diabetes, and for the development of more targeted prevention, screening, 
monitoring and treatment approaches. 
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Panel 12: Cloud-based health information systems  
Cloud-based health information systems offer the possibility of capturing data from 
multiple sources and devices in real-time and the integration of these data, for 
monitoring, analysis, and decision support to improve management of diabetes. 
 
One example of the use of cloud-based health information solutions is the expansion 
in Mozambique of almost 18,000 modules of the Xpert MTB/RIF system through the 
TBXpert Project, managed by the WHO Global Tuberculosis Programme and the 
Stop TB Partnership Secretariat.374  
 
The Xpert system is an automated, cartridge-based nucleic amplification assay for 
the detection of tuberculosis and rifampicin resistance from sputum in less than two-
hours. The scale-up of this system has been accompanied by the development of a 
range of cloud-based services that integrate data collected through these devices into 
online ‘data clouds’.x Data in the data clouds have been used to produce real-time 
disease monitoring information at the level of individual patients, populations, 
geographical regions, as well as at the level of the laboratories and staff responsible 
for operating these devices. Such data have improved decision support for 
stakeholders, ranging from individual patients, clinical practitioners and public 
health officials, involved in the management of tuberculosis. 
 
As a complex disease that is associated with tuberculosis, HIV, high blood pressure, 
ischaemic heart disease and cancer, diabetes provides an excellent entry point to 
introduce the use of cloud-based health information systems in SSA to improve the 
management of NCDs. Such cloud-based systems could help mitigate several barriers 
to effective diabetes care in SSA. First, data cloud solutions are lower costs and 
scalable as compared with traditional data storage systems that rely on hard drives or 
other hardware that require constant electricity supply. Second, there is no need to 
buy expensive hardware or to service them. Third, by integrating data from multiple 
devices and sources, cloud-solutions can help manage the complex data needed 
across multiple facilities, levels and over long periods of time for management of 
diabetes. Fourth, diabetes in SSA is characterised by its heterogeneity. Pooling 
patient data in cloud-based health information systems across various settings and 
levels will enable better understanding of the epidemiology, geographic and 
population coverage, and the responses to interventions (e.g. based on geography, 
treatment regimen, as well as genotype and phenotype characteristics), and offer the 
possibility of developing better targeted policies and intervention approaches for 
diabetes.  
 
Improving the adoption and diffusion of new health technologies for 
diabetes care in sub-Saharan Africa 
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The third challenge that needs to be addressed in relation to technology relates to 
addressing factors that hinder adoption and diffusion of new technologies. These factors 
include inadequate definition of the problem being addressed, complexity and scalability 
of the technology or intervention, resistance from the adoption system (health 
professionals and service users for example), characteristics of the health system that 
create rigidity or provide inadequate incentives, and poor appreciation or recognition of 
the challenge of diabetes in the broader context (among the population and the 
politicians) so that it is not seen as an urgent and major societal challenge. 375,376, 
 
Existing and new technologies that can address distinctive needs of populations and 
health systems in SSA could have substantial and positive impact on health outcomes in 
these countries. Yet, the availability of new technologies for diabetes care in SSA and the 
use of existing technologies have been patchy.  
 
Improving management of diabetes and health outcomes will only be possible by 
investing in R&D and innovation to develop necessary technologies that do not exist, 
ensuring technologies that exist are accessible, and enabling rapid adoption and 
diffusion of accessible technologies. However, SSA should not replicate Western models, 
but develop health systems with innovative delivery models for diabetes that reflect the 
African context.  
 
As with HIV377, new models of care delivery are emerging for management of diabetes in 
SSA, with distinctive features that uses a public health approach with simplification and 
decentralisation, strong reliance on non-physician health workforce including nurses, 
community health workers and health extension workers, community involvement, peer 
support and, self-management strategies, underpinned by efforts aimed at strengthening 
health systems. 
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Elements of a successful response to diabetes in in sub-
Saharan Africa  
 
The Commission findings reveal rapidly rising prevalence of overweight and obesity, type 
2 diabetes, and gestational diabetes in SSA. Little is known about the prevalence of type 1 
diabetes. In SSA the interaction of diabetes with infectious diseases, further increase the 
burden of illness on resource constrained weak health systems.  
 
Our analysis has shown that health systems in SSA are unprepared for managing the 
current burden of diabetes and the impending epidemic. As a result, many people go 
undiagnosed, those that are diagnosed are not screened for comorbidities, do not receive 
treatment, or are not adequately controlled. The resultant morbidity and mortality is 
therefore high, with very large human, economic and societal consequences.  
 
Whilst some countries in SSA achieved good progress towards health-related-MDGs 
(often enabled by donor funded vertical programs) health expenditures from domestic 
sources remain low.  Apart from notable exceptions (for example Tanzania and 
Ethiopia), few countries have actionable plans to manage the complexities of caring for 
diabetes and NCDs. In-country data systems are too weak to allow reliable estimates of 
prevalence of diabetes and related comorbidities, creating further challenges for health 
system planning.  
 
Disease-specific initiatives are generally launched on the presumption that the condition 
in question is a clearly defined entity with well-established therapeutic rules for its 
management. Diabetes, a life-long condition associated with multiple vascular risk 
factors and sequelae, requires a more nuanced approach, for its prevalence reflects not 
just a disease but a changing phenotype. A complex and heterogeneous disorder such as 
this cannot be managed effectively without the understanding and co-operation of the 
person involved, and effective prevention requires increased awareness and education 
within the community as a whole. Hence, specific therapeutic measures are not enough; 
successful management of diabetes requires creation of a medical, social and political 
context within which lifelong care can be delivered. In this respect, there are lessons to 
be learned from the HIV response in Africa, which brought together governments, civil 
society, healthcare providers, community, donors and private sector.   
 
The sheer burden of diabetes in SSA and its impact on individuals, populations, health 
systems and economies, means that governments must act to bring together wide 
ranging stakeholders to spur action at country and global level. 
 
Government responsibilities 
  
Ultimately, governments should respond to the wishes of their populations. In addition 
to enabling individuals to access health services, governments must introduce public 
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health measures to impact NCDs. Government interventions to ban smoking in public 
places, restrict advertising, increase taxes on cigarettes and sugar sweetened beverages, 
and limit portion size of sugar sweetened beverages have reduced demand and 
consumption.378  
 
A health-literate population is critical for generating demand, improving access to health 
system and ensuring uptake of preventative measures. Much of the increase in health 
literacy in SSA has come from successful media campaigns via radio, poster adverts, and 
education via interaction with CHWs. These campaigns have generally focussed on 
prevention of HIV (e.g. condom use) and malaria (e.g. use of insecticide treated bed 
nets). Investment is needed to increase population’s awareness of diabetes and to 
generate demand. Therefore, we recommend that countries in SSA consider developing 
media campaigns to educate the public about the symptoms of type 1 and type 2 diabetes 
and encourage those with symptoms to seek care. In particular, media campaigns should 
be deployed to educate citizens about preventative lifestyle measures, combined with 
government regulations that limit advertisements for unhealthy foods. 
 
In addition to population level public health measures to improve health literacy, given 
the strong causal link between NCDs (including type 2 diabetes), sugar sweetened 
beverages, salt, and tobacco, we strongly advise countries to consider raising revenues by 
taxing these products to pay for health care provision. Although all-too- often considered 
as a disease of the rich, in LMIC the burden of type 2 diabetes and its comorbidities is 
increasingly being born by the poor379. Encouraging healthy choices and taxing 
unhealthy choices should help promote health of the poorer sectors of society, whilst 
raising revenue for treasuries to finance health systems and expand access to health 
services, medicines and diagnostics. 
 
Many governments in SSA have limited fiscal space against competing demands for 
funding. There should be concerted efforts to expand fiscal space in order to increase 
investment in health. Hence, taxes on tobacco, unhealthy foods and sugar sweetened 
beverages to expand fiscal space, should be combined with national plans for diabetes 
that can drive system-wide changes to improve efficiency and reduce waste, while 
improving health outcomes. In order to develop sustainable plans to manage diabetes, 
governments should undertake a health system assessment to ascertain what needs to be 
done to establish an effective response for dealing with the burden of diabetes. Such an 
assessment should detail the burden of diabetes and its co-morbidities, their 
management at all levels of the health system, and how the services and platforms 
developed for communicable diseases can best be leveraged to also provide services for 
diabetes. A detailed exploration of the capability of human resources, availability of 
drugs and equipment and their costs (both to the health system and individuals), and 
functioning of supply chain management should be part of this assessment. 
 
Governments should prioritise data collection for the improvement of their population 
health. There is an urgent need for countrywide integrated digital health information 
systems to collect data on diabetes (including a diabetes registry), its comorbidities, and 
	 63	
their management in the health system. Governments face multiple pressures to provide 
data on global targets. Countries should prioritise data collection systems, which could 
be used for health system planning at local and national level, and also inform global 
targets.  
 
Governments should allocate sustainable funding to tackle the diabetes epidemic. We 
have calculated that in 2015 the economic burden of diabetes in SSA was $27.24 billion 
or 1.33% of cumulative GDP of the whole of SSA. Unchecked, the estimated economic 
burden is projected increase to $120.35 billion by 2030, equal to 5.64% of GDP in 
Southern Africa, 3.48% in Eastern Africa, 3.11% in Middle Africa and 1.39% in Western 
Africa.  
 
Diabetes and its sequelae can be treated cost-effectively. Most of the medicines required 
for treating diabetes that are on the WHO 2015 essential medicines list are off-patent 
and are relatively low cost. In addition to anti-diabetic medicines, off-patent drugs such 
as ACE inhibitors should be made available to protect against diabetic nephropathy 
(including enalapril, which is currently listed as an antihypertensive on WHO list of 
essential medicines) and diabetic retinopathy380.  Insulin is a special case, as generic 
forms are not widely available. However, countries can purchase vials of human insulin 
at prices comparable cost per person per year to that paid for one-year supply of fixed-
combination ARV treatment. Given the absolute need for insulin treatment for type 1 
diabetes and increasing need for type 2 diabetes, human insulin should be widely 
available for all those who need it. We consider that in the context of low-income 
countries of SSA, more expensive analogue insulins do not provide enough extra benefit 
to justify the current prices, as argued by Beran et al.381 
 
Considering treatment, we urge countries to make all necessary medicines on the WHO 
essential medicine list for diabetes, hypertension, and cardiovascular disease available at 
no cost to all patients who need them. Newer treatments for type 2 diabetes may have 
some benefit over standard oral anti-hyperglycaemic agents and insulin. However, we 
would only consider these a worthwhile investment for the public sector after the 
countries in SSA have been able to provide essential services and medicines for diabetes. 
 
There is a clear need to educate all groups of health professionals – ranging from 
community health workers to specialist physicians at all levels of the health system – on 
the management of diabetes along the care continuum to enable increased detection 
improved treatment. This need is especially great in settings dealing with children, so 
that a diagnosis of type 1 diabetes is not, fatally, missed. It is also essential in perinatal 
care and infectious disease clinics, to ensure diagnosis and treatment of gestational 
diabetes and to effectively manage interactions between diabetes and communicable 
diseases. Once recognised, diabetes – especially type 2 – can be effectively managed. 
Hence, we would advise countries to consider leveraging the existing human resources 
by training them to diagnose and treat diabetes before investing in training specialist 
diabetologists.   
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The sequelae of diabetes are insidious and present late in the disease course. Their 
effective management requires yearly monitoring at well-equipped health centres for 
glycaemic control and other cardiovascular risk factors in order to improve micro-
vascular outcomes such as retinopathy, nephropathy, and diabetic foot. 
 
Civil Society 
 
Civil society plays a critical role in demanding change to improve access to health care 
and holding governments to account. Advocacy from civil society was instrumental in the 
global movement for HIV, which prompted the convening of a special session of the UN 
General Assembly in 2001 and led to the first UN declaration focusing on a disease.382 
Civil society can frame diabetes as integral part of the global commitments to address 
NCDs and to achieve UHC, given its links to so many risk factors and conditions, and use 
this narrative for awareness building and mobilising support among a broad of 
stakeholders.  
 
Effective deployment of civil society requires strengthening and expanding networks in 
SSA, an increase in the health literacy of the population and improved modes of 
communication. In many of the countries in SSA, foundations are playing a key role in 
educating the public, health care providers, and governments about diabetes. Diabetes 
foundations should catalyse the continuing improvement in management of diabetes by 
tracking progress towards objectives set out in national NCD or diabetes plans and 
holding governments account for their implementation. However, funding is needed to 
ensure that their work can continue and expand. We urge donors and diabetes 
foundations in other countries to consider funding and, or partnering with foundations 
in SSA to enable mutual learning, strengthen the agenda for change and ensure 
sustainability. 
 
Of particular urgency is the matter of T1DM, where it is suspected, although not 
definitively known, due to lack of data, that the majority of sufferers may die without a 
diagnosis or access to treatment. Civil society should play a key role in raising awareness 
of T1DM and they should ensure that governments are held to account regarding 
guaranteeing a supply of insulin to all sufferers, not just children 
 
To date, most international health NGOs have focused their efforts on maternal, 
neonatal, and child health, communicable diseases, and on providing health care in 
conflict settings. While some NGOs, such as Life for a Child 
(http://www.idf.org/lifeforachild) and Sante Diabete 
(http://www.santediabete.org/en/), have focussed on diabetes, these are far and few. It 
is encouraging to note that MSF is increasing its involvement in NCDs. 
 
Whilst recognising the importance of focusing on their core business, we encourage 
NGOs working in SSA to recognise the importance of diabetes and obesity in their 
patient populations and, where possible, work in concert with country health systems to 
find solutions to incorporate improving diabetes care. This is particularly important for 
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NGOs who deal with communicable diseases and improving maternal and neonatal 
health, where diabetes impact on outcomes.  
 
Donors 
 
While NCDs have been identified as a priority at the 2011 UN High Level Commission, 
with renewed commitment in health SDG, they still do not feature prominently on the 
agendas of most global health funders, whose assistance to countries has plateaued. To 
date, donor agencies have channelled their funding to meeting MDGs while the growing 
epidemic of T2 Diabetes, and its precursors (overweight and obesity), have received 
limited support – especially T1DM, which has 100% mortality rate without treatment, 
but can be effectively managed.  
 
Overweight, obesity, and diabetes are often perceived as ‘lifestyle’ problems and lack the 
prominence of maternal, neonatal, and child health, communicable diseases. Yet, 
evidence strongly suggests overweight, obesity, and diabetes are influenced more by 
environment than individual factors. NCDs, which include diabetes, are now the major 
cause of morbidity and mortality in LMICs, and there is an imperative to invest in their 
management if the health gains due to improvements in maternal, neonatal, and child 
health, communicable diseases are to be sustained. Hence, donors should transition 
channelling funds to vertical disease programmes but invest in health systems improving 
health of individuals, who all so often have multiple ailments.  
 
Global agencies 
 
Global agencies have been slow to transition to a new world where NCDs predominate. 
In 2011, the United Nations High Level Meeting on NCDs383 produced the UN General 
Assembly Resolution on the prevention and control of NCDs384, committing the UN 
member states to prevention and control of NCDs385. In 2013, at the 65th World Health 
Assembly member states agreed to reduce premature mortality from NCDs by 25% by 
the year 2025 relative to their 2010 levels.386 However, in spite of these resolutions and 
targets apathy prevails.387 Although a global coordination mechanism, a monitoring 
framework, an action plan, and an UN interagency task force have been established, it is 
not clear what has been achieved to positively impact on the lives of those living with 
NCDs. As with many countries globally, health systems in SSA are not ready for the rapid 
demographic, epidemiological, social and economic transition that has brought rising 
levels of diabetes along with multimorbidity and disability.388,389  
 
As with the Ebola crisis, the response of WHO to NCDs, the world’s predominant global 
health agency has been lacklustre. Yet, there is an opportunity. WHO is well respected in 
SSA countries and is well placed to play a leadership role to address diabetes – and not 
just in SSA but globally. However, this opportunity can only be realised if WHO reflects 
on the criticisms390 (for example lack of leadership, sluggish responses, and 
introspection) and learns lessons from the Ebola crisis to emerge as a leader in the battle 
against diabetes and NCDs.  
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Learning from the lessons of the Ebola crisis, WHO has the opportunity and the 
legitimacy to work with member states, international agencies and civil society 
organisations to mount an urgent and coordinated response to the burgeoning diabetes 
epidemic. The coordination among partner institutions should be replicated internally 
among WHO departments. As a start, we urge WHO to make available global diabetes 
data available to researchers wishing to do analyses to help improve the health systems 
of people in countries in SSA and globally.391  
 
While WHO has the potential to lead coordinated action, an urgent response to diabetes 
in SSA can only be achieved with decisive contribution of international institutions such 
as the World Bank, with its financing and development capability and expertise in health 
systems, the Global Fund, which can catalyse an integrated response to bring together 
communicable diseases, MNCH and NCDs, GAVI, with its capability in innovative 
financing and cold chain development, UNITAID, in creating market dynamics and 
expanding access to new technologies and medicines, USAID, which has successfully 
helped countries to scale up MNCH and reproductive health response and is now 
championing integration and quality improvement, and among others, UNICEF to build 
on the effective platforms established for managing children’s problems.  
 
We urge all multi and bilateral global health and development agencies to recognise the 
importance of preventing and treating diabetes in order for SSA to achieve the SDG goals 
and to avert an economic burden that will arrest development. 
 
Research, development and innovation 
 
A global response to diabetes would be incomplete without an ambitious research and 
development (R&D), and innovation agenda to address the scale and urgency of 
diabetes. There is an urgent need to scale up research and learning to improve 
functioning of health systems.392 There is also a need to invest in R&D and innovation in 
development of new low cost technologies and medicines, which are affordable in SSA, 
as well as innovations in financing and service delivery393 to address resource shortages 
and accelerate adoption and diffusion of existing and new technologies in health 
systems394. An enabling environment is critical for ensure effective adoption of complex 
innovations – such as novel primary health care services395,396 – which are critical for 
establishing a comprehensive health system response. 
 
Current global shortage of health professionals is a major barrier to expanding services 
in SSA. While additional human resources are needed, resource constraints mean that in 
the near term rapid expansion in numbers is not realistic. Addressing human resource 
shortages will require a combination of strategies. The first of these strategies is task 
shifting, which has been effectively implemented in several countries of SSA to use a 
broader group of health professionals in diabetes care (se Section 7). The second strategy 
is to use novel technologies to improve the knowledge and competences of existing 
health workforce, by leveraging advances in communications, including distance 
	 67	
learning and e-learning through use of online courses397. The third, among others, is to 
use mobile technologies and SMS text messaging to better manage communications and 
processes in health systems, for example in communicating results398, attending 
appointments in clinics399, rapidly scaling up public health interventions and prevention 
to population400, and to improve self-management of long-term illness by patients 
themselves401.  
 
There are also opportunities for increasing financing diabetes. In spite of the global 
economic crisis, countries in SSA have achieved sustained economic growth, and are 
projected to do so in the next decade.402 In addition, innovative financing (such as 
Airline Solidarity Levy and Debt2Health), which has been used successfully for AIDS, 
tuberculosis, malaria and children’s immunisation programmes, offers possibilities for 
mobilising, pooling, channelling and funding health systems and diabetes.403,404 as well 
as late stage research405.   
 
Targets 
 
Countries are overwhelmed with goals, targets and indicators. There are 17 Sustainable 
Development Goals (SDGs) with The third SDG (Ensure healthy lives and promote well-
being for all at all ages) alone has 13 targets. Of these, six targets are most readily 
applicable to diabetes as targets for SSA. These include:  
(i) By 2030, reduce by one third premature mortality from non-communicable 
diseases through prevention and treatment 
(ii) Achieve universal health coverage, including financial risk protection, access to 
quality essential health-care services and access to safe, effective, quality and 
affordable essential medicines and vaccines for all 
(iii) Strengthen the implementation of the World Health Organization 
Framework Convention on Tobacco Control in all countries, as appropriate 
(iv) Support the research and development of vaccines and medicines for the 
communicable and noncommunicable diseases that primarily affect developing 
countries, provide access to affordable essential medicines and vaccines 
(v) Substantially increase health financing and the recruitment, development, 
training and retention of the health workforce in developing countries, especially 
in least developed countries 
(vi) Strengthen the capacity of all countries, in particular developing countries, for 
early warning, risk reduction and management of national and global health risks 
 
In addition, at the 65th World Health Assembly member states approved the WHO 
Global Action Plan for the Prevention and Control of NCDs 2013-2020 nine voluntary 
targets to reduce premature mortality due to NCDs by 25%, reduce physical inactivity by 
10%, reduce tobacco consumption by 30%, achieve a 25% reduction in high blood 
pressure, achieve 80% coverage of essential medicines and technologies for NCDs and 
achieve 0% increase in the prevalence of obesity and diabetes by the year 2025.406 The 
Global Action Plan is underpinned by the Global Monitoring Framework with 25 
indicators that are monitored by member states – of which 12 are relevant to diabetes.407  
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Achieving the targets set in the SDGs, and the Global Action Plan will transform the 
management of diabetes in SSA and help avert needless suffering, illness and death, and 
reduce the economic burden of diabetes on individuals, households and societies. The 
critical ingredient to an effective response to diabetes in SSA is solidarity and collective 
action at local, national, African and Global level – collective action, which lies at the 
heart of sustainable diabetes response and sustainable development in SSA. 
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